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1. INTRODUCTION 
 Oral drug delivery system is considered to be one of the most convenient and     
commonly employed drug delivery system as it possesses some specific advantageous              
characteristics, such as ease of administration, least aseptic constraints and flexibility in the 
design of the dosage form. Another revolution towards the oral drug delivery is the modified 
release dosage forms which have huge advantages over immediate release formulations of the 
same drug. There are different methods for the designing of this modified dosage form, some of 
them are film coated pellets, tablets, capsules or more sophisticated and complicated delivery 
systems such as osmotically driven systems, systems controlled by ion exchange mechanism, 
systems using three dimensional printing technology and systems using  electrostatic deposition 
technology. The modified release products are usually designed to provide slow and continuous 
delivery of drug over the entire dosing interval and improve patient compliance and 
convenience1,2,3. Recently, the most common widely used controlled delivery system is the 
matrix type where the drug is uniformly entrapped in to the polymer4,5. In formulation of oral 
controlled release formulation, hydrophilic polymers are most frequently used as polymeric 
retardant materials due to their ease of manufacturing, relatively low cost, favorable in vivo 
performance and versatility in controlling the release of drug with wide range of 
physicochemical properties6-11.The release of highly water soluble drug inherently follows near 
first-order diffusion with an initially high release rate. The enhanced release rate observed at the 
beginning within a short period of time and it is known as burst effect, sometimes it is 
undesirable as it can have some negative therapeutic impact (i.e. toxicity due to increase of the 
concentration of the delivered substance beyond maximum therapeutic concentration).After this 
burst effect, hydration and consequent swelling and/or erosion of retard polymer occurs. These  
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phenomena control the release process but sometimes this result in a progressively slow release 
rate as due the increasing of the diffusion path-length, as a result of which ultimately a saturation 
effect is attained6-11. A number of factors that are used to overcome this undesirable behavior and 
release pattern of drug from polymeric matrix include physicochemical properties of drug 
(solubility, viscosity, etc.),content of drugs and polymers in matrices,drug/polymer weight ratio, 
route of administration,and manufacturing process12-19. 
 The another new drug delivery concept is the control release of drug form the dosage 
form where the drug is released from the dosage form in a constant manner in respect to time but 
without depending upon the initial concentration of the drug and hence the release of drug from 
this type of dosage form follows zero order release kinetics.This drug delivery system has been 
widely used as drug delivery system for the drugs having low therapeutic index to reduce the 
dose dumping. To alter the kinetics of drug release from inherent non-linear behavior to linear 
include the use of geometry factors (solid units having spherical, cylindrical, conical, biconcave, 
biconvex, donut shapes, hemisphere with cavity, core in cup, circular sectioned cylinder, rings, 
oval bi-dose divisible tablets etc.), films, erosion/dissolution controlled and swelling controlled 
mechanisms, non-uniform drug loading and matrix-membrane combination20-33. Among all the 
above techniques, multi-layered matrix tablet pay more attention as drug delivery devices to the 
research scientist. 
Multi-layered matrix tablet comprises a matrix core containing the active solute(s) and one, or 
more barriers (modulating layers) incorporated during the tabletting process. The function of the 
modulating layers is to delay the interaction of active solute with dissolution medium by limiting 
the surface available for the solute release and at the same time controlling solvent penetration  
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rate through the matrix34,35,36. In this design, the coat layers prevent the water                                                                                                          
penetration and thus protect the core. This ultimately reduced the hydration rate and controlled 
area for solute release at the core. Thus burst effect can be minimized and the release can be 
maintained at a relatively constant level during the barrier layers’ swelling and erosion process. 
After this phase, during the subsequent portion of the dissolution process, these swollen barriers 
are erosion dominated and the surface available for drug  release slowly increases. In this way 
the decrease of delivery rate due to the increase of diffusion path-length (saturation effect) is 
counter balanced by the simultaneous increase of the area available for drug release35. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                     3 
PLAIN MATRIX TABLET 
 
MULTILAYERD TABLETS (SWELLABLE BARRIERS) 
 
MULTILAYERD TABLETS (ERODIBLE BARRIERS) 
 
Figure 1: Effect of the application of polymeric layers (barriers) on the release of drug              
               from a matrix core. 
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 A linear release profile is achieved by combining a time-dependent control of the   
hydration rate of the device with the reduction of tablet surface exposed to the dissolution 
medium. It is also possible to obtain various dissolution patterns such as multi modal,       
pulsatile or delayed delivery, extended release (characterized by reasonably constant rate) for 
different drugs by varying the formulations of layers. The major criterion for all of this      
application is the multi-layered system should swell gel and finally erode completely, leaving 
negligible residue in the gastro-intestinal tract36.The system overcomes the major         
disadvantage of non-linear release associated with most diffusion controlled matrix devices. 
Beside the above, this system also has the advantage of being compatible with conventional 
manufacturing methods. From the word ‘Bilayer Tablet’ indicates that it is a solid oral dosage 
form, usually round, spherical, oval or biconcave in shape and consist of one or more than one 
medicaments designed in a two layers system which can be suitable for combination therapy and 
biphasic release therapy. In case of combination therapy the two layers of this tablet is consist of 
two different medicaments and in case of bi-phasic release bilayer tablet both the layers content 
same drugs but the drug from one layer is immediately release and the drug release from the 
second layer is released for an extended period of time to maintained the therapeutic 
concentration of drug within therapeutic window. For the formulation of  layers from different 
polymers manipulation has been done over more than one rate-controlling polymers and thus 
allow different types of drug delivery of one or more drugs, i.e. where the drug may be released 
with a bolus and then as a controlled rate or by targeted drug delivery in the GI tract using pH 
dependent polymers so in the formulation of bilayer tablets the polymer plays a very important 
role. 
 Other than the polymer there are clearly a number of issues which should be taken into 
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consideration during the production of bilayer tablets. Such as the mechanical strength of bilayer 
tablets, it has been observed that it do not play an important role as the controlling factor in drug 
release, but  the determination of this property is very essential as it could be beneficial in 
understanding the adhesion property  between various layers and finally providing an improved 
characterization of the systems. 
 
Figure 2:  In case of combination therapy the drug 1 and drug 2 are different but in case of 
sustained release the drug 1 is the loading dose where as the drug 2 is the maintenance dose 
of a drug 
 
1.1 ADVANTAGES OF BILAYER TABLET 
 Before explaining the advantages of bilayer tablet, here are the advantages of the tablet 
dosage form over the dosage form are as follows: 
 Tablet is a unit dosage form and they offer the greatest compatibilities of all oral     
dosage forms for the greatest dose precision and the least content variability. 
 The cost is approximately lower than any other oral dosage form. 
 These are very compact in nature. 
 In general the packaging procedure for tablets are easier and cheaper. 
 Swallowing of tablets is very easy. 
 They are better suited to large scale production. 
 Chemically, mechanically and microbiologically tablets are very stable. 
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The advantages of the ‘bilayer tablet’ over the other conventional preparations of  
            oral solid dosage forms include. 
 When the two different layers of the tablet content two different drugs, then the tablet 
can be easily used in combination therapy. 
 This formulation can be use to deliver separate two incompatible substance. 
 In case of drugs having a low half life, each of the two layers of the tablet respectively 
content a loading dose and maintenance dose of the same and thus increase the     
bioavailability of the drug. 
 Frequency of the dose administration is reduced which ultimately improve the patient 
compliance. 
 In case of a conventional dosage form due to fluctuation of the dose interval the plasma 
drug concentration may differ (under medication or over medication), but in this dosage 
form the plasma drug concentration is always constant, which ultimately provide a more 
effective action of the drug. 
 Better control of drug absorption can be attained, since the high blood level peaks that 
may be observed after administration of a dose of high availability drug can be       
reduced by formulation in an extended action form. The safety margin of high        
potency drugs can be increased and the local and systemic adverse effects can be   
reduced in sensitive patients. 
1.2 LIMITATIONS OF BILAYER TABLET 
 From the above mentioned advantage of bilayer tablets it is quite clear that in      
pharmaceutical industry it is a great revolution, but there are certain limitations in the       
formulation and use of bilayer tablets, such as: 
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 One of the major challenges in bilayer formulation is lack of sufficient bonding and 
adhesion at the interface between the adjacent compacted layers which is often the  result 
of an interfacial crack and layer separation. 
 If the compacted layers are too soft or too hard, they will not bind securely with each 
other which can lead to compromised mechanical integrity and also the separation of the 
layers. 
 Other challenges during development include establishing the order of layer sequence, 
layer weight ratio, elastic mismatch of the adjacent layers, first layer tamping force, and 
cross contamination between layers. 
 The adjacent layers of a bilayer tablet are bonded together by mechanical means, so the 
factors influences the stress state is very important. The mechanical properties of each 
layer and the tablet, and compression parameters along with specialized techniques and 
compression condition plays a very important role for the same. 
 Administration of sustained release bilayer tablet does not permit the prompt          
termination of therapy. 
 The physician has a less flexibility on adjusting the dose regimens. 
1.3 GMP REQUIREMENTS FOR BILAYER TABLET 
 To produce a quality bi-layer tablet, in a validated and GMP-way, it is very important to 
follow the following criteria for the selection of bilayer press. These requirements seem obvious 
but are not so easily accomplish. The press should be capable of 
 Preventing capping and separation of the two individual layers that constitute the bi-layer 
tablet 
 Providing sufficient tablet hardness 
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 Preventing cross-contamination between the two layers 
 Producing a clear visual separation between the two layers 
 Manufacturing products of high yield 
 Accurate and individual weight control of the two layers 
1.4 DRUG RELEASE MECHANISM 
 Normally the drug release from hydrophilic swellable matrices depends on the       
polymer macromolecular coupling, relaxation and the drug diffusion11-14 and all of these are 
responsible on the rate at which water may penetrate into the device. Hydration rate, swelling of 
the polymer and modification of the polymer matrix are the basics for the multilayered drug 
delivery design. These factors are very effective at the primary or initial phase of the drug 
dissolution but with the respect of time as swelling proceeds linearization of the release profile 
occurs. To achieve this objective, coating of the matrix tablets with an inert impermeable film 
has been performed. Coating plays a very important role in the drug release from the 
multilayered preparations and a number of combinations of coating materials are used that is 
schematically represented by Figure 3. The release rate of the drug from    tablets is observed by 
in vitro release rate study. The release rate of the drug is inversely  proportional to the extent of 
coating. The release of the drug is primarily dependant on the swelling of the polymer which is 
again controlled by reducing the drug release surface by the coating material. 
 When a tablet is coated partially, it does not swell and retain its initial size and shape and 
maintain the release retardation continuously through the entire dissolution process35. On the 
other hand, when the tablet is subjected to water immersion the polymer barrier which is inert in 
nature have a tendency to crack and separated out from the core within hours. This effect is 
resulted from volume expansion of core upon water immersion due to polymer swelling. The  
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outer barrier layer does not expand while the core is swelling as a result a stress is generated in 
the outer barrier layer. When the outer barrier is sellable polymer then the both barrier and core 
swell simultaneously without any internal stress during the dissolution process. Multilayer 
compression process can be used for the application of barriers. One notable example of this 
phenomena is the double layer or three layer tablets in which only one layer contains the active 
ingredient (active core), while other layers are barrier layers. 
 
 
Figure 3: Schematic representation of the matrix tablet (a) and of the four partially       
coated designs 
 The multi-layer design allows for the production of different tablet designs by varying the 
geometry of the device or modulating layers characterized by specific release properties to 
achieve various dissolution patterns (not limited to a constant release) such as delayed, pulsatile 
or multi modal delivery profiles. The section below deals with various tablet possibilities based  
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on this proposed design. 
1.5 DIFFERENT STRATEGY OF DRUG RELEASE: 
1.5.1 Release of drug follows zero-order release kinetics 
 Zero order release means where the release of the drug occurred without being       
dependant on the initial concentration of the drug. This system consists of either a              
hydrophilic or hydrophobic layer containing the active ingredients or one or two barrier    layers. 
These barrier layers are coated to the faces of the tablet core and the sides of the core remain 
exposed. The polymers widely used as barrier for sustaining the drug delivery are  either 
hydrophilic or hydrophobic materials. Linear release profiles is usually obtained by applying 
hydrophilic barrier layers on either the sides of a hydrophobic matrix tablet or by applying a 
hydrophilic barrier layer on any one side and hydrophobic barrier layer on the  other side of the 
matrix tablet. However, net formulation and variables within the matrix and barrier layers must 
be controlled to get zero-order release of drug from hydrophilic matrix tablet coated with 
hydrophobic barrier layers on both the faces37-40. 
1.5.2 Fast/slow release system 
 In case of designing a dosage form of quick/slow release delivery system an initial rapid 
release phase is designed by the application of immediate release layer to the conventional 
layered matrix tablet. Where a drug is initially rapidly released from a dosage form and then 
followed by a slow release rate. The burst release can suddenly raise the plasma drug 
concentration which can produce a rapid rise in plasma levels for those drugs that are required to 
show appearance promptly for the therapeutic effect, followed by an extended release of drug at 
a constant rate for prolonged period of time. A versatile quick/slow delivery system can be 
designed one of which is Naproxen quick/slow system developed by Maggi et al 41. This system 
proved bioequivalence with marketed tablet Naprosyn SR. Thus the quick/slow delivery system 
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is very essential in certain conditions like where sudden increase of plasma drug concentration is 
essential for the purpose of getting therapeutic activity immediately as well as to reduce dose 
frequency and thereby to improve patient compliance41,42,43. 
1.5.3 Time-programmed delivery system (press coated tablet) 
 In certain disease conditions, the rate and behavior of drug release should be          
controlled with respect to time, as because of maintenance of constant drug plasma           
concentration is not required for desired therapeutic activity. The drug release behavior should be 
controlled in respect to time along with the rate of drug release, as because to  maintain always a 
constant drug plasma concentration is not required for the optimal or  desired therapeutic 
activity. Therefore, a drug with optimal concentration should be delivered in target site with 
respect to time for getting the required activity. In order to reduce the     incidence of tolerance 
and to follow the innate circadian rhythm, the most accepted form of the drug delivery system 
should be such that the dosage forms capable of release the drug in a pulsatile fashion rather than 
continuous release44,45,46,47. For this purpose, various system like time clock system have been 
developed using different technique and functional polymers or additives48,49,50,51. 
 Press coating technique is one of the novel drug delivery system that not only controls the 
release of drug but also deliver the drug in gut. No special coating solvent or equipments and 
manufacturing speed is faster are the main advantages of this techniques. Either         
conventional or modified release formulation core system is used in this system and the core 
layer may further coated by different polymers with the help of compression process52,53. This 
system delivers the drug from the core tablet after swelling or eroding of the hydrophilic or 
hydrophobic barrier of the coating shell to exhibit a pulsatile manner of drug release54,55,56,57. The 
function of this outer shell is to protect the core layer and delay the drug release by prolonging 
the lag time prior to the start of drug release and control the fluid penetration. This device can be  
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considered as a reservoir system this phenomenon is not dependent on the composition of the 
core rather on the shell structure and presence of expandable polymer in the shell. After the fluid 
penetration the interior core of the tablet swelled up and by breaking the outer shell rapidly 
releases the drug57,58,59. 
PRESS-COATED TABLETS - ERODIBLE SHELL 
 
PRESS-COATED TABLETS – GELLABLE SHELL 
 
Figure 4: Geometric press coated tablets for delayed release . 
1.5.4 Bimodal release profile 
 In designing of control release system it is considered that the system should release the 
drug in a zero-order rate, thereby to maintain the plasma drug concentration in a constant level. 
However, in actual practice for many drugs, absorption is moderately slow in the stomach, rapid 
in the proximal intestine, and gradually lowered in the distal segment of the intestine. Hence to 
design constant drug absorption, the dosage form should be able to release the drug in a varying 
manner, thereby the release can compensate the change in the drug absorption in the different 
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part of the gastrointestinal tract and provide a control release of the drug. This kind of release 
pattern can be obtained with the help of bimodal release system. This release system is consisted 
of an initial rapid release layer, which is then followed by a period of slow and constant release, 
and again a second phase of rapid drug release60. In this delivery system an additional layer 
known as the fourth layer containing initial dose rapidly disintegrates to produce a quick 
dissolution onset which ultimately provide a concentration gradient to compensate the poor 
absorption in stomach. With the help of barrier layers from the sustained release portion drug 
release is controlled.  The pH of the large intestine initiates the second rapid drug release. The 
advantages of this system over others systems, (i) this dosage form can produces rapid drug 
release during the initial phase and in the later phase compensate the relatively slow drug 
absorption in the stomach and large intestine and (ii) it can be used to design programmed pulse 
release oral drug delivery systems for the therapeutic agents that can perform more effectively or 
give more therapeutic activity when drug levels at the site of   action undergo periodic changes. 
1.6 VARIOUS TECHNIQUES FOR BILAYER TABLET 
1.6.1. Osmotic-controlled release oral delivery system 
 In this technology the system is consist of mainly two or three layer among which  one or 
more layer are of the drug and other layers are consist of push layer. The drug layer mainly 
consists of poorly soluble drug along with diluents, low molecular weight polymer, suspending 
agent and osmotic agent. The push layer is constructed of a higher molecular weight 
osmopolymer and an osmagent. A semi permeable membrane surrounds the tablet core. In this 
technology the medication is sandwiched with an osmotic agent that swells when it takes up 
water. The sandwich is then coated with a semi permeable membrane .Then a laser is used to 
drill a tiny hole through the membrane. In the stomach, water passes through the membrane into  
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the pill, causing the osmotic material to swell, which pushes the drug out of the hole. This 
delivers the drug to the body at a constant rate instead of all at once, as happens when a 
traditional pill dissolves.  Products manufactured using this technology are Glucotrol Xl and 
procardia XL both of which are  composed of a bilayer tablet core and Concerta is compose of a 
trilayer tablet core. 
 
 
1.6.2 Elan drug technology (DUREDUS technology) 
 DUREDAS or Dual Release Drug Absorption System (Elan Corporation) utilizes   
bilayer-tabletting technology, which has been specifically developed to provide two different 
release rates or dual release of a drug from a single dosage form. The tablets are prepared by two 
separate direct-compression steps that combine an immediate-release granulate (for rapid onset 
of action) and a controlled-release hydrophilic matrix complex within one tablet. The immediate 
release layer, release the drug immediately after going into the GIT (stomach or intestine) in a 
diffusion and dissolution manner and the controlled-release matrix remains  intact and slowly 
absorbs fluid from the GI tract, which causes the matrix to expand and transforms the 
hydrophilic polymers into a porous, viscous gel that serves as a barrier   between the drug and  
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Figure 5: Preparation of bilayer and trilayer tablet 
by OROS push pull technology 
the surrounding fluid. As the gel continues to expand, fluid penetrates further into the dosage 
form, dissolving the drug and allowing the resulting solution to diffuse out in a controlled 
manner. A further extension of the Duredus technology is the production of controlled-release 
combination dosage forms whereby two different drugs are incorporated into the different layers, 
and the drug release of each is controlled to maximize therapeutic effect of the combination. 
Again both immediate release and controlled release combinations of the two drugs are feasible. 
The DUREDAS™ technology was initially employed in the development of a number of over 
the counter controlled release analgesics. 
Figure 6: DUREDAS technology consists of control release and immediate release layer. 
Figure 7: DUREDAS technology consist of two control release layers. 
                                                                                                                                               16 
1.7 INFLUENCE OF PROCESS AND FORMULATION PARAMETERS 
 As the initial dose layer do not affect the intermediate slow release or the second rapid 
phase or constant phase release, this layer is not necessary to be considered in the formulation 
process. Multi-layered tablet consisting of a core and one or more barrier layers should be taken 
into account while determining the parameters involved in the processing. The following factors 
should be considered for the process and formulation61,62. 
1.7.1 Parameters dealing with the layer consisted of therapeutically active substances 
 During granulation of therapeutically active substances some basic factors are to be 
considered which includes percentage of the liquid used in granulation, time required for 
massing step, temperature of the outlet air during the drying step and milling screen apertures as 
well as the interaction between the amount of granulation liquid and the outlet temperature [63]. 
While the impact of these factors on the final products has to be considered and the responses 
can be classified into four categories: (i) granules properties (e.g., flowability, bulk density, 
ability to settle, particle size distribution), (ii) extensometric responses (e.g. cohesion index, 
lubrication index, ejection strength, plasticity, elasticity), (iii) physical characteristics of tablet 
(e.g. thickness, weight variation, hardness, friability) and (iv) analytical results (e.g. content 
uniformity, in vitro profile). 
1.7.2 Compression process 
 The critical parameters in the compression process are turntable speed and compression 
forces corresponding to first, second and main layers. The tablet crushing strength response 
improves when the turret compression speed on the main compression force is increased. But 
these parameters (within a particular range) do not influence the content uniformity and the 
release performances in multi-layered, press coated and, bimodal delivery systems63. But in the 
case of press coated tablet intended for distant destination (e.g. colon targeting) the release rate      
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and lag time are dependent on the compression force. The release rate of drug decreases and the 
lag time increases with increasing compression force till a critical point. After this point 
increasing compression force does not provide further reduction in porosity. There is necessity of 
increasing the lag time more than 10 h in the gastric fluid under some physiological conditions64 
and also there is need for suppression of release in the intestinal fluid for more than 3 h in order 
to obtain colon targeting. To achieve these certain additives, which have poor wettability, are 
added to the outer shell polymer to prevent the penetration of dissolution medium into the pores 
in the outer shell. For example, magnesium stearate or calcium stearate were added to the 
hydroxyl propyl methyl cellulose acetate succinate (HPMCAS) polymer to increase the lag time. 
Eiji Fukui et al.58 reported that the drug release in gastric fluid was completely suppressed until 
15 h if  tablets containing magnesium stearate irrespective of compression force and for tablets     
containing calcium sterate, it was necessary to increase the compression force to more than the 
range applied, to suppress until 12 h. In the intestinal fluid the lag time was not prolonged to 
more than 2 h by addition of magnesium stearate. In contrast lag time could be prolonged by 
calcium stearate as long as 9 h by increasing the compression force. The above results suggested 
that press coated tablets intended for colon targeting mainly depends on compression force when 
poor wettable additives are used. 
1.7.3 Hardness of compressed tablet 
 The resistance of tablets to shipping or breakage under conditions of storage, 
transportation and handling before usage depends on its hardness. The hardness of tablet of each 
formulation was measured by Monsanto hardness tester. The hardness was measured in kg/cm2. 
 Hardness of tablet is expressed in terms of tensile strength. The tensile strength of the 
tablet is calculated by the formula, according to Fell and Newton65. 
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σ = 2P
πDt 																																												(1) 
 
where r = tensile strength (kg/cm2), D= tablet diameter (cm), t = tablet thickness (cm), P= force 
applied to fracture (kg). The porosity of the tablets decreased by the rise of tensile strength which 
is ultimately depends on the compression load. Since the compression force (particular range) 
does not affects the release rate, therefore, hardness of the tablet (generally in layered 
construction) has less significance in the formulation. 
1.7.4 Polymer concentration in core 
 Polymer is one of the most important factors that influence the release of drug from the 
tablets. With the increase of the polymer concentration usually the dissolution rate of the tablet is 
decreased. This parameter does not affect the drug release in layered tablets as     considerably in 
the bimodal tablet because the solubility of certain polymers depends on the pH of the 
surrounding medium. For example  the effect of decreasing HPMCAS-MF amounts in the inner 
layer of bimodal delivery system is not significant in pH 1.2 but in pH 7.4 drug release increases 
with decrease in the amount of polymers63. At high pH values a less dense polymer network 
dissolves more rapidly than a tight structure, leading to increased drug release rate. At low pH 
HPMCAS-MF is not soluble, thus there is no effect on the breakdown of the polymer network. 
Therefore, concentration of pH sensitive retard polymers in the core should be controlled more 
closely. 
1.7.5 Filler 
 Filler used in the core of the tablet, has a great influence on the drug release rate     
because of its solubility. On contact with the release medium, the filler diffuses out from the 
device and thereby affect the drug release rate by increasing the porosity of polymers.  
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     Depending upon the amount of the filler the amount of the polymer is adjusted to keep the 
tablet weight constant. Example of such filler is lactose. 
1.8 VARIOUS COMBINATIONS OF BILAYER TABLETS 
 Table 1 indicates the different formulations of bilayer tablet containing combination of 
two drug and their specific uses. Table 2 indicates the different formulation of bilayer tablet 
containing the same drug in both fast release layer and sustained release layer. Table 3 indicates 
the different bilayer tablet formulation available in the market. 
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Table 1: Bilayer tablets containing two drugs in an individual layer. 
Drug Drug Purpose Ref. 
Metformin 
hydrochloride 
Glimepiride 
 
Improve oral therapeutic efficacy with optimal 
control of plasma drug level 
66 
Metformin 
hydrochloride 
Pioglitazone 
 
Reduce frequency of administration and improve 
patient compliance 
67 
Paracetamol 
 
Diclofenac                     
sodium 
Reduce dose frequency and decrease incidence of GI  
 
side effects  
 
68 
Tramadol 
 
Acetaminophen Prolonged release up to 12 h and improve patient  
 
compliance 
69 
Salbutamol 
 
Theophylline Enhance patient compliance and prolong       
 
bronchodilation 
 
70 
Metoprolol 
Succinate 
Amlodipine 
besylate 
Lower doses of drug to reduce patient 
blood pressure, minimize dose dependent side effects 
and adverse reactions 
71 
Diltiazem 
hydrochloride 
Lovastatin 
 
Improve patient compliance and better disease 
management 
72 
Atorvastatin 
calcium 
Nicotinic acid Develop potential dosage form 73 
Metoclopramide 
hydrochloride 
Ibuprofen 
 
Effective treatment of migraine and avoid    chemical 
incompatibility between drugs 
74 
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Table 2: Bilayer tablets containing the same drug in an immediate release layer and 
sustained release layer. 
Drug Fast release 
layer/Backing 
membrane 
Sustained 
release layer 
Remarks Ref. 
Indomethacin 
(Floating 
tablet) 
Ac-di-sol HPMCK4M Release the drug from fast release 
layer within 2h and followed by 
sustained release for24h.Reduce 
dose frequency and improve 
patient compliance 
75 
Propanolol 
Hcl 
(Bucoadhesive 
tablet) 
Ethylcellulose Sodium 
alginate and 
carbopol 971P 
Tablets containing sodium alginate 
and   carbopol 971P in the ratio of 
5:1 had the  maximum percentage 
of in vitro drug release without 
disintegration in 2 h. 
76 
Guaifenesin 
(Matrix tablet) 
Microcrystalline 
cellulose,      
Sodium starch 
glycolate 
Metalose 
90SH,    
Carbopol 934 
Burst release of drug (over 20%) 
within first half an hour and 
followed by sustained release for 
12 h. 
77 
Atorvastatin 
calcium 
Mucoadhesive 
buccal tablet) 
Ethylcellulose Carbopol934P,       
Sodium CMC,        
Hydroxyethylc
ellulose,Sodiu
m alginate 
 
The optimized formulation 
performed 6h sustained drug 
release with desired therapeutic 
concentration 
78 
 Propanolol 
Hcl (Matrix 
tablet) 
 
Sodium starch 
glycolate 
 
Ethylcellulose,        
Eudragit 
RLPO and 
Eudragit 
RSPO 
 
Over 30% of propanolol HCl was 
released within 15 min and 
followed by sustained release for 
12 h. 
 
 
 
 
79 
Zolpidem 
tartarate 
(Matrix tablet) 
Cross-        
carmellose    
sodium 
HPMC 
K100M 
Optimized formulation released 
more than 50% of drug within the 
first 30min  and remaining drug 
released could be extended  
upto 6 h. 
80 
Fenoverine 
(Floating 
tablet) 
Cross-          
carmellose     
sodium 
HPMC K4M, 
HPMC 
K100LV 
Loading dose of the drug was 
released within 10-15 min and 
followed by zero-order sustained 
release upto 12 h. 
81 
Verapamil 
hydrochloride 
(Floating 
tablet) 
Crosspovidone, 
Sodium starch 
glycolate 
HPMC K15M, 
HPMC 
K100M, 
Carbopol 971P 
Immediate release layer get 
completely dissolved within 15-20 
min and 30-45% drug released 
among the total dose. Concurrently 
floating sustained release layer 
released the drug upto 12 h. 
82 
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Table 3: Commercially marketed bilayer tablets 
Product Name Chemical Name Developer 
ALPRAX PLUS Sertraline, Alprazolam Torrent Pharmaceutcals Ltd. 
Glycomet®-GP2Forte Metformin hydrochloride, 
Glimepiride 
USV Limited 
Newcold Plus Levocetrizine           
hydrochloride,          
Phenylpropanolamine, 
Paracetamol 
Piramal Healthcare Ltd. 
DIAMICRON®XRMEX500 Gliclazide,Metformin 
hydrochloride 
Sedia® Pharmaceuticals 
(India) Pvt. Ltd. 
DIUCONTIN-K®20/250 Furosemide,Potassium chloride T.C. Health Care Pvt. Ltd. 
Tribet-1 Glimepiride,         Pioglitazone               
hydrochloride,          Metformin         
hydrochloride 
Abbott Healthcare Pvt. Ltd. 
Revelol®-Am 25/5 Metoprolol succinate, 
Amlodipine besilate 
Ipca Laboratories Ltd. 
PIOKIND®-M15 Pioglitazone, metformine 
hydrochloride 
Psychotropics India Ltd. 
TRIOMUNE 30 Nevirapine, Lamivudine, 
Stavudine 
Cipla Ltd. 
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2.REVIEW OF LITERATURE 
 
1.Bhavesh S et al (2008)bilayer tablets are prepared with one layer of drug for immediate release 
while second layer designed to release drug, later, either as second dose or in an extended release 
manner. Bi-layer tablet is suitable for sequential release of two drugs in combination, separate 
two incompatible substances, and also for sustained release tablet in which one layer is 
immediate release as initial dose and second layer is maintenance dose. Bi-layer tablet was 
suitable for preventing direct contact of these two drugs and thus to maximize the efficacy of 
combination of two drugs for  any dieseas83. 
  
2. Nagaraju R et al(2009) bilayer tablets are novel drug delivery systems where combination of 
two or more drugs in a single unit having different release profiles which improves patient 
compliance, prolongs the drug(s) action, avoid saw tooth kinetics resulting in effective therapy 
along with better control of plasma drug levels. Bi-layer tablets are very common for drugs such 
as captopril, metoprolol, amoxicillin and potassium clavulanate, propranalol hydrochloride, 
bambuterol hydrochloride84 etc 
 
3. Saleh MAS et al (2005)the  study was to develop guar gum matrix tablets for oral controlled 
release of water-soluble diltiazem hydrochloride. In pharmaceuticals, guar gum is used in solid 
dosage forms as a binder and disintegrant. Guar gum is a nonionic polysaccharide. Matrix tablets 
containing 2 different proportions of various viscosity grades of guar gum were prepared by wet 
granulation method find the utility of guar gum in providing controlled release. The guar gum 
matrix tablet formulation providing an optimal in vitro drug release was subjected to further 
studies to investigate its in vivo performance in healthy volunteers. and subjected to in vitro drug 
release studies85. 
 
4.Chinam np et al (2007) the objective of the present research was to develop a bilayer tablet of 
propranolol hydrochloride using super disintegrant sodium starch glycolate for the fast release 
layer and water immiscible polymers such as ethylcellulose,  Eudragit RLPO and Eudragit RSPO 
for the sustaining layer. In vitro dissolution studies were carried out in a USP 24 apparatus 
Statistical analysis (ANOVA) showed no significant difference in the cumulative amount of drug 
release after 15 min, but significant difference (p < 0.05) in the amount of drug  released after 
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12 hours from optimized formulations was observed86. 
 
5. Faith A et al (2010)hydrophilic matrix formulations are important and simple technologies 
that are used to manufacture sustained release dosage forms. Method, Hydroxypropyl 
methylcellulose-based matrix tablets, with and without additives, were manufactured to 
investigate the rate of hydration, rate of erosion, and  mechanism of drug release. The results 
revealed that the rate of hydration and erosion was dependent on the polymer combination(s) 
used, which in turn affected87 . 
 
6. Uttam M  et al (2008) the emerging new fixed dose combination of Metformin hydrocholride  
as sustained release and glipizide as immediate release were formulated as a bilayer matrix tablet 
using hydroxy propyl methyl cellulose (HPMC) as the matrix-formingpolymer, and the tablets 
were evaluated via in vitro studies.The release kinetics of metformin were evaluated using 
theregression coefficient analysis. Tablet thus formulated provided sustained release of 
metformin HCl over a period of 8 hours and glipizide as immediate release88. 
 
7. Raghuram RK et al (2003)the present study was to develop once-daily sustained-release 
matrix tablets of nicorandil, a novel potassium channel opener used in cardiovascular diseases. 
The tablets were prepared by the wet granulation method. Ethanolic solutions of ethylcellulose 
(EC), Eudragit RL-100, Eudragit RS-100, and polyvinylpyrrolidone were used as granulating 
agents along with hydrophilic matrix materials like hydroxypropyl methylcellulose (HPMC), 
sodium carboxy methyl cellulose, and sodium alginate. The results of dissolution studies 
indicated that formulation F-I (drug-to-HPMC, 1:4; ethanol as granulating agent) could extend 
the drug release up to 24 hours. In the further formulation development process, F-IX (drug-to-
HPMC, 1:4; EC 4% wt/vol as granulating agent), the most successful formulation of the study, 
exhibited satisfactory drug release in the initial hours, and the total release pattern was very close 
to the theoretical re-lease profile89. 
 
8. Anna K et al (2009)the effect of three different types of polymer chain structures on the 
polymer release from hydrophilic matrix tablets was investigated by comparing a synthetic 
semicrystalline linear polymer (PEO), a branched amorphous polysaccharide (dextran) and an 
amorphous substituted cellulose derivative (HPMC). The polymer release rates for tablets was   
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determined by using a modified USP II method and a SEC-RI chromatography system. This 
confirms the hypothesis that the release rate can be related to a constant viscosity on the surface 
of the hydrophilic matrix tablet and that it is valid for all the investigated polymers90. 
 
9. Jose MCB et al (2010)poly(carboxyalkyl methacrylates) were studied as a cationic-drug 
delivery system, at pH 6.8 and 8.0. Different polymer/ drug complexes were used to prepare 
compressed tablets. By kinetics experiments, we have found that drug releaseis dependent on 
both the hydrophobicity of the whole complex and the pH of the environment. Furthermore, 
amechanism of dissociation/erosion clearly describes the drug release from a complex formed by 
a polymer solubleat target pH; otherwise, a mechanism of dissolution/diffusion is depicted. Since 
our results using different polymer/drug complexes exhibitpH-sensitive drug release, we propose 
that the poly(carboxyalkyl methacrylates) have potential as a colon-specificdrug-delivery 
system.91  
 
10. Vanna S et al (2004) the study was the preparation of bilayer tablets asrumen-stable delivery 
systems, designed for the oral administration of active ingredients (folic acid) to ruminants. In 
vitro rumen-protection tests were performed in buffer systems at pH 5.5 and pH 2.0, simulating a 
ruminal and abomasal environment, to verify the stability of bilayer tablets at these conditions. 
The tablets having layer B constituted by poly (e-caprolactone) or Eudragit RS do not 
disintegrate in buffer media at pH 5.5 and pH 2.0, and they are characterized by a sustained 
release at pH 7.4. Radiological preliminary tests show that these prepared bilayer tablets are able 
to be retained in the reticulum–rumen tract of the sheep92 
 
11. Mukesh G et al (2009) this research work was to develop venlafaxine hydrochloride-coated 
and layered matrix tablets using hypromellose adopting wet granulation technique. The granules 
and the tablets were characterized. The monolithic tablets were coated with different ratios of 
ethyl cellulose and hypromellose. The invitro dissolution study was performed in distilled water. 
The monolithic tablets were coated with different ratios of ethyl cellulose and hypromellose. The 
invitro dissolution study was performed in distilled water. The layered tablets also exhibited 
sustained release without burst effect due to effective area reduction. Layered tablets may well 
be adopted by the industry due to the possibility of achieving a highproduction rate93 
 
12. Yassin El-Said H et al (2010) the proposed strategy was based on preparing directly  
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compressed hydroxypropylmethylcellulose matrix tablets to sustain lornoxicam release. Basic 
pH-modifiers, either sodium bicarbonate or magnesium oxide, were incorporated into these 
matrix tablets to create basic micro-environmental pH inside the tablets favorable to drug release 
in acidic conditions. All the prepared matrix tablets containing basic pH-modifiers showed 
acceptable physical properties before and after storage. Release studies,performed in simulated 
gastric and intestinal fluids used in sequence to mimic the GI transit, demonstratethe possibility 
of sustaining lornoxicam release by combining hydrophilic matrix formers and basic pH 
Modifiers to prepare tablets that meet the reported sustained-release specifications94 
 
13. Chuan-Yu Wu et al (2009)the compaction behaviour of binary mixtures and bilayer tablets 
of two common pharmaceutical excipients, Microcrystalline cellulose and lactose, is 
investigated. The effects ofcompositions and compaction pressure on the compaction behaviour 
of binary matrix mixtures and bilayer tablets are also explored. The delamination phenomena 
during the manufacturing of bilayer tablets and fracture patterns of tablets subjected to 
diametrical compression are examined using X-ray computed tomography. It was also found 
that, using the same compaction process, the relative densities of the tablets were generally 
different when different compositions were used, especially when the maximum compression 
pressure is relatively low95. 
 
14. Harikrishna B et al (2009)  matrix tablet formulation has been used to develop controlled 
release diltiazem HCl  tablets..The developed drug delivery system provided prolonged drug 
release rates over a defined period of time.DIL tablets prepared using dry mixing and direct 
compression and the core consisted of hydrophilic and hydrophobic polymers such as 
hydroxypropylmethylcellulose, Eudragits RLPO/RSPO, microcrystalline cellulose, and lactose. 
The release profile of the developed formulation was described by the Higuchi model. Stability 
trials up to 6 months displayed excellent reproducibility96. 
15. S.Mohamed Halith et al (2011), Formulated and evaluated of bilayer tablets of amlodipine 
besilate and metprolol succinate and have done on DSC studies  formulation and compare to 
pure compound Heat flow rates were measured over a temperature range of 30°C - 300°C at a 
heating rate of 15°C/min for Amlodipine Besilate pure drug, placebo and tablet samples. 
Similarly temperature range of 25°C- 250°C at a heating rate of 5°C/min was used for  
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Metoprolol Succinate pure drug, placebo, and tablet samples97.        
16. Vaijanath G.  et al,.(2008)  Simultaneous determined  metoprolol succinate and amlodipine 
besylate in pharmaceutical dosage form by HPLC. The mobile phase consisting of buffer 
(aqueous triethylamine pH 3) and acetonitrile in the ratio of 85: 15 (v/v) at a flow rate of 1.0 
ml/min was used. The method was validated according to the ICH guidelines with respect to 
specifity, linearity, accuracy, precision and robustness98. 
17. Prasada Rao et al., (2010)developed a simple, rapid and selective HPLC method developed 
for quantization of Amlodipine Besylate and Metoprolol succinate from bulk drug and 
pharmaceutical formulations using a mobile phase consisting mixture of 0.02 M phosphate 
buffer solution and Acetonitrile as 80:20 at the flow rate of 1 mL/min. An Inertsil ODS-CV 
column was used as stationary phase. The retention time of Amlodipine Besylate and Metoprolol 
succinate were 3.92 and 10.43 respectively99 
18. V.Rajamanickam et al.,(2010) developed and validate a economic, rapid reversed-phase 
high-performance liquid chromatographic method for the quality control of Metoprolol succinate 
and amlodipine besylate in pharmaceutical preparations with lower solvent consumption along 
with the short analytical run time leads to an environmentally friendly chromatographic 
procedure that allows the analysis of a large number of samples in a short period of time100. 
19. N.N.Rajendran et al,(2010)  investigated the effect of a novel drug- drug solid dispersion 
approach on the dissolution of hydrochlorothiazide in a fixed dose combination with Losartan 
potassium Solid dispersions by differential scanning calorimetry, x-ray diffractometry and 
dissolution tests and the results were compared with that of pure drugs and physical mixtures. 
Solid dispersion as well as physical mixture were then compressed into tablets and evaluated for 
physicochemical, stability and dissolution characteristics and the results compared with 
commercial tablets101. 
20. Chuan-Yu et al.,(2009) described the compaction behavior of binary mixtures andbilayer      
tablets of two common pharmaceutical excipients, microcrystalline   cellulose    and lactose. 
Thedelamination phenomena during the manufacturing  of     bilayer tablets and fracture patterns 
of tablets subjected to diametrical compression are examined using X-ray computed to 
monography. The mechanical properties of binary  and bilayer tablets of the same composition                     
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were also determined and compared102. 
21. Jakkie et al.,(1997) reported the effect of V-mixer size on the mixing of magnesium stearate 
with directly compressible microcrystalline cellulose and evaluated the mixing process and 
compare the performance of the mixers, the extent of the decrease in tablet crushing strength was 
measured. The kinetics of the decrease in crushing strength were best described by the sum of 
two separate processes, one first-order and the other second-order. Overall, the faster second-
order process dominated mixing because the first-order rate decreased, while the second-order 
rate increased. with an increase in mixer volume. Results showed that the limiting crushing 
strength increased with an increase in mixer size and that there was a linear relationship between 
the limiting crushing strength and the logarithm of the volume of the mixer. A decrease in mixer 
load from 33 to 18% also led to an decrease in tablet strength103. 
 
 22. Calum et al.,(2002) developed bilayer mucoadhesive tablets of Nicotine evaluated to 
determine the suitability of the formulation as a Nicotine replacement product to aid in smoking 
cessation. A combination of 20% w/w carbopol 934 and 20% w/w Hydroxypropylcellulose was 
found to provide suitable adhesion and controlled drug release. The formulation of bilayer tablet 
containing the adhesive controlled release layer and a fast releasing layer provided an initial 
burst release of drug followed by the controlled release for a period of upto 4 hours104. 
23. Miyazaki et al.,(2000) developed potential of bilayer tablets containing 1:4, 1:1 and 4:1 
weight ratios of pectin and HPMC for the sustained release of Diltiazem by sublingual 
administration has been investigated. An in vitro sustained release of Diltiazem over 5 hours was 
achieved with bilayer tablets composed of a drug-free ethyl cellulose layer in addition to the 
pectin/HPMC layer containing drug. Bioavailability of Diltiazem was 2.5 times than achieved by 
oral administration for single layer tablets and 1.8 time for the bilayer tablets105. 
24. Anil Chaudhary et al.,(2011) prepared microporous bilayer osmotic tablet bearing 
dicyclomine hydrochloride and diclofenac potassium by using a new oral drug delivery system 
for colon targeting. The tablets were coated with microporous semi permeable membrane and 
enteric polymer using conventional pan-coating process. The number of pores was dependent on 
the amount pore former in the semi permeable membrane. In vitro dissolution results indicated 
that system showed acid resistance, timed release was able to deliver drug at an approximate zero  
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  order up to 24 hour106.  
25. Carmen et al.,(1998) prepared new buccal delivery devices comprising a drug containing 
mucoadhesive layer and a drug free backing layer, by two different methods. The mucoadhesive 
layer was composed of a mixer of drug and chitosan, with or without an anionic cross linking 
polymer (polycarbophill, sodium alginate, gellan gum), and the backing layer was made of ethyl 
cellulose. The double layered structure design was expected to provide drug delivery in a 
unidirectional fashion to the mucosa and avoid loss of drug due to wash out with saliva. Using 
nifedipine and propranolol hydrochloride as slightly and highly water soluble model drugs, 
respectively, it was demonstrated that show promising potential for use in controlled delivery of 
drugs to the oral cavity. The uncrosslinked chitosan containing devices absorbed a large quantity 
of water, jelled and then eroded allowing drug release. The bilaminated films shows a sustained 
drug release in a phosphate buffer (pH 6.4)107 
26. Yong Shao et al.,(2005) used electrochemically synthesized conducting polymer polypyrrole 
(PPy) film on gold electrode surface was used as a novel support for bilayer lipid membrane 
(BLMs). The   formation of PPy supported bilayer lipid membranes (s-BLMs) is dependent on  
the chemical structure of the lipid use108. 
 27. Fridrun Podczeck et al.,(2010) determined the tensile strength of bilayer tablets made from 
different grades of microcrystalline cellulose. While these grades are chemically identical, they 
differ significantly in their particle size distribution and in their mechanical properties such as 
young’s modules of elasticity. Both particle size and Young’s modules of elasticity influenced 
the overall strength of layered tablets. If the material forming the lower layer was more elastic, 
then the beam strength was reduced due to tension introduced into the system, acting especially 
at the layer interface and potential causing partial or complete delamination109. 
 
28. Ajit Kulkarni et al.,(2009) Developed of regioselective bilayer floating tablets of Atenolol 
and Lovastatin for biphasic release profile. In DSC studies the tablet was ground to powder 
and a 1-2 mg sample was hermetically sealed in an aluminum pan and heated at a constant rate 
of 10°C/min, over a temperature range of 50-200 °C. Inert atmosphere was maintained by 
purging nitrogen gas at a flow rate of 20 ml/min d110.                                                                                     
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 29. A. Streubel et al.,(2010) developed new multi-layer matrix tablets to achieve bimodal drug  
release profiles (fast release /slow release / fast release). Hydroxypropyl  methylcellulose acetate 
succinate (HPMCAS, type MF) as a matrix former, because it   is water-insoluble at low, and 
water-soluble at high pH values. The addition of a fourth, drug-containing and fast disintegrating 
initial dose layer yielded the desired bimodal drug  release patterns. The process and formulation 
parameters affecting the resulting release rates  using theophylline and acetaminophen as model 
drugs111. 
 
30. Rashmi Dahima et al.(2010) increased the solubility and dissolution rate of amlodipine     
besylate   by the preparation of its solid dispersion with cross povidone using solvent evaporation   
method. Drug polymer interactions were investigated using differential scanning calorimetry    
(DSC) and Fourier transform infrared spectroscopy (FTIR). Surface morphology of solid  
dispersion particle determined by SEM study. Dissolution rate of solid dispersion was  
determined in 0.01 N HCl at 75 rpm. The obtained results showed that dispersion of the drug  in 
the polymer considerably enhanced the dissolution rate. It revealed that crosspovidone in  solid 
dispersion itself act as superdisintegrant and binder and an optimum concentration of a  
pregelatinized starch is required for obtaining rapidly disintegrating tablets. The potential of  
experimental design in understanding the effect of the formulation variables on the quality of  
mouth dissolving tablets containing solid dispersion of a hydrophobic drug112. 
 
31. Naeem et al.,(2010) developed and characterized bilayer tablet formulations of tramadol HCl 
(TmH) and acetaminophen (AAP) microparticles. Coacervation via temperature change the 
encapsulated method used for the preparation of the microparticles, with ethyl cellulose (EC) of 
medium viscosity as the polymer for extending drug release. FTIR, XRD, DSC and TGA data for 
the formulations indicate good compatibility and stability. Furthermore, accelerated stability 
studies confirmed the stability of the formulations. Controlled drug release from the 
microparticles and bilayer tablets was observed for 8 h and 12h, respectively. Microencapsulated 
TmH and AAP can be developed into suitable bilayer tablets that are stable and capable of 
releasing the drugs over 12hours113. 
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 32. L. Yang et al.,(1997) formulated components were poly(ethylene oxide) (PEO), lactose, and 
theophylline. Results indicate that the formulation of each layer and the combined triple-layer 
tablet exhibited similar compression behavior, and the consolidation mechanism was shown to 
follow predominantly plastic deformation as evidenced by the shape of Heckel plots and high 
SRS (Strain Rate Sensitivity) values. A triple-layer tablet formulation necessitates careful 
selection of plastic, brittle, and other desirable components to ensure comparable compactibility 
profiles114. 
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3.AIM AND PLAN OF WORK 
 
The aim  of  the  present  study  is  to  formulate  and  evaluate  film  coated  tablets of 
                         Amlodipine besylate and Losartan Potassium. The work will be scheduled as: 
 
1. To develop suitable analytical method for the estimation of the drug. 
             2.   To Perform Preformulation studies 
             3.   Formulation and evaluation of Bilayer tablets: 
 Formulation of Immediate- release granules of Amlodipine Besylate. 
 Formulation of Immediate-release granules of Losartan Potassium. 
 Evaluation of Immediate- release granules of Amlodipine Besylate 
 Evaluation of Immediate-release granules of Losartan Potassium. 
 Compression of bilayer tablets. 
 Evaluation of compressed Bilayer tablets 
            4.   Optimization  of  formulation  parameters  and  drug-carrier  system  using 
      appropriate methods. 
            5.   Stability studies of the most satisfactory formulation will be carried out as  
                  per ICHguidelines. 
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                                               4.DRUG PROFILE 
 
                Amlodipine Besylate115,116 
                  Category              : Cardio vascular agent , calcium channel blocker  
 Empirical Formula : C20H25 cl N2O5 
 Molecular Weight : 408.876   
Structure Formula: 
 
Chemical Name: 3-Ethyl-5-methyl (±)-2-[(2-aminoethoxy) methyl]-4-(2-chlorophenyl)-1, 4-
dihydro-6-methyl-3, 5-pyridinedicarboxylate, monobenzenesulphonate 
Physiochemical Properties 
 Appearance, odour and Colour: A white or almost white powder. 
 Melting Point:  195 - 204 C 
 Solubility: Slightly soluble in water, freely soluble in methanol; sparingly soluble  in         
                                     anhydrous ethanol, slightly soluble in 2-orooanol. 
PHARMACODYNAMICS 
 Amlodipine belongs to the dihydropyridine (DHP) class of calcium channel blockers 
(CCBs), the most widely used class of CCBs. There are at least five different types of calcium 
channels in Homo sapiens: L-, N-, P/Q-, R- and T-type. It was widely accepted that DHP CCBs .         
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target L-type calcium channels, the major channel in muscle cells that mediate contraction; 
however, some studies have indicated that Model drug 1 also binds to and inhibits N-type 
calcium channels. Similar to other DHP CCBs, Model drug 1 binds directly to inactive L-type 
calcium channels stabilizing their inactive conformation. Since arterial smooth muscle 
depolarizations are longer in duration than cardiac muscle depolarizations, inactive channels are 
more prevalent in smooth muscle cells. Alternative splicing of the alpha-1 subunit of the channel 
gives GEN001 additional arterial selectivity. At therapeutic sub-toxic concentrations,Amlodipine 
has little effect on cardiac myocytes and conduction cells. 
MECHANISM OF ACTION 
 Amlodipine is a dihydropyridine calcium antagonist (calcium ion antagonist or slow-
channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth 
muscle and cardiac muscle. Experimental data suggest that Model drug binds to both 
dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac 
muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium 
ions into these cells through specific ion channels. Amlodipine inhibits calcium ion influx across 
cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac 
muscle cells. Negative inotropic effects can be detected in vitro but such effects have not been 
seen in intact animals at therapeutic doses. Serum calcium concentration is not affected by 
Model drug. Within the physiologic pH range, Amlodipine is an ionized compound (pKa=8.6), 
and its kinetic interaction with the calcium channel receptor is characterized by a gradual rate of 
association and dissociation with the receptor binding site, resulting in a gradual onset of effect. 
Biological Properties 
 cLogP  : 3.43400 
 LogP  : 2.0 
 pKa  : 8.6 
 Cmax  : 5.14 ng/ml 
 T max  : 6 – 12 hours 
 Half-life (Mean) : 30-50 hours 
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Pharmacokinetics 
Absorption:  
 Amlodipine is slowly and almost completely absorbed from the gastrointestinal tract. 
Peak plasma concentrations are reached 6-12 hour following oral administration. Its estimated 
bioavailability is 64-90%. Absorption is not affected by food.  
 Distribution: Ex vivo studies have shown that approximately 95%of the circulating 
GEN001s bound to plasma proteins in hypertensive patients. 
 Metabolism: Hepatic. Metabolized extensively (90%) to inactive metabolites via the 
cytochrome P450 3A4 isozyme. 
Excretion 
 Amlodipine is extensively (about 90%) converted to inactive metabolites via hepatic 
metabolism with 10% of the parent compound and 60% of the metabolites excreted in the urine. 
Dosage: Maximum dose of 10 mg daily.  
Contraindications: 
 Amlodipine (Besylate) is contraindicated in conditions like Aortic Stenosis 
PRECAUTIONS:  
General:  
 Since the vasodilation induced by Amlodipine is gradual in onset, acute hypotension 
has rarely been reported after oral administration. Nonetheless, caution, as with any other 
peripheral vasodilator, should be exercised when administering Amlodipine, particularly in 
patients with severe aortic stenosis. 
Use in Patients with Congestive Heart Failure:  
 In general, calcium channel blockers should be used with caution in patients with 
heart failure. Amlodipine (5 to 10 mg per day) has been studied in a placebo-controlled trial of       
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1153 patients with NYHA Class III or IV heart failure (see CLINICAL PHARMACOLOGY) on 
stable doses of ACE inhibitor, digoxin, and diuretics. Follow-up was at least 6 months, with a 
mean of about 14 months. There was no overall adverse effect on survival or cardiac morbidity 
(as defined by life-threatening arrhythmia, acute myocardial infarction, or hospitalization for 
worsened heart failure). Amlodipine has been compared to placebo in four 8-12 week studies of 
patients with NYHA class II/III heart failure, involving a total of 697 patients. In these studies, 
there was no evidence of worsened heart failure based on measures of exercise tolerance, NYHA 
classification, symptoms, or LVEF. 
Beta-Blocker Withdrawal:  
 Amlodipine is not a beta-blocker and therefore gives no protection against the 
dangers of abrupt beta-blocker withdrawal; any such withdrawal should be by gradual reduction 
of the dose of beta-blocker. 
Patients with Hepatic Failure:  
 Since Amlodipine is extensively metabolized by the liver and the plasma elimination 
half-life (t 1/2) is 56 hours in patients with impaired hepatic function, caution should be 
exercised when administering Amlodipine to patients with severe hepatic impairment. 
 Amlodipine interactions: In vitro data indicate that Amlodipine has no effect on the 
human plasma protein binding of digoxin, phenytoin, warfarin, and indomethacin. 
Effect of other agents on Amlodipine 
 CIMETIDINE: Coadministration of Amlodipine with cimetidine did not alter the 
pharmacokinetics of Amlodipine. 
 GRAPEFRUIT JUICE: Coadministration of 240 mL of grapefruit juice with a single 
oral dose of Amlodipine 10 mg in 20 healthy volunteers had no significant effect on the 
pharmacokinetics of Amlodipine 
MAALOX (antacid): Coadministration of the antacid Maalox with a single dose of amlodipine                      
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 had no significant effect on the pharmacokinetics of Amlodipine. 
  Effect of Amlodipine on other agents . 
 ATORVASTATIN: Co administration of multiple 10 mg doses of Amlodipine with 
80 mg of atorvastatin resulted in no significant change in the steady state pharmacokinetic 
parameters of atorvastatin. 
 DIGOXIN: Co administration of Amlodipine with digoxin did not change serum 
digoxin levels or digoxin renal clearance in normal volunteers. 
 ETHANOL (alcohol): Single and multiple 10 mg doses of Amlodipine had no 
significant effect on the pharmacokinetics of ethanol. 
 WARFARIN: Co administration of Amlodipine with warfarin did not change the 
warfarin prothrombin response time. 
 In clinical trials, Amlodipine has been safely administered with thiazide diuretics, 
beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual 
nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral 
hypoglycemic drugs. 
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Losartan Potassium116 
 
                Category           : Cardio vascular agent , angiotensin II receptor        
                                                                                                                     antagonist  
                   Molecular Formula         : C22H23ClN6O  
                Molecular Weight          :422.9 
                               Structure: 
 
 
 
 
 
 
 
 
 
 
 
 
             Systematic (IUPAC) name : 
 
                        (2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol- 
 
                                                                                                                                5-yl)methanol 
 
Pharmacodynamics: 
 
Losartan is an Angiotensin II receptor antagonist drug used mainly to treat high blood pressure 
 (hypertension). Losartan was the first angiotensin II receptor antagonist to be marketed.  
Losartan potassium is marketed by Merck & Co. Inc. under the trade name Cozaar. As of 2009,  
losartan is available in generic form. As with all angiotensin II type 1 receptor (AT1) antagonists,  
losartan is indicated for the treatment of hypertension. It may also delay progression of diabetic 
nephropathy, and is also indicated for the reduction of renal disease progression in patients with  
type 2 diabetes, hypertension and microalbuminuria (>30 mg/24 hours). Although clinical  
evidence shows calcium channel blockers and Thiazide-type diuretics are preferred first-line  
treatments for most patients (from both efficacy and cost points of view), an angiotensin II 
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receptor antagonist such as losartan is recommended as first-line treatment in patients under the  
age of 55 who cannot tolerate an ACE inhibitor. The LIFE study demonstrated losartan was  
significantly superior to atenolol in the primary prevention of adverse cardiovascular events  
(myocardial infarction or stroke), with a significant reduction in cardiovascular morbidity and  
mortality for a comparable reduction in blood pressure. A study hints that losartan has a  
beneficial effect on mitochondria by reversing age related dysfunction in maintaining normal  
blood pressure and cellular energy usage. The maximal effects on blood pressure usually occur  
within 3-6 weeks upon starting losartan.  
                Losartan is also available as hydrochlorothiazide/losartan, a combination drug with a  
low dose thiazide diuretic to achieve an additive antihypertensive effect. 
 
Mechanism of action: 
           Losartan is a selective, competitive angiotensin II receptor type 1 (AT1) receptor  
antagonist, reducing the end organ responses to angiotensin II. Losartan administration results in  
a decrease in total peripheral resistance (afterload) and cardiac venous return (preload) All of the  
physiological effects of angiotensin II, including stimulation of release of aldosterone, are  
antagonized in the presence of losartan. Reduction in blood pressure occurs independently of the  
status of the renin-angiotensin system. As a result of losartan dosing, plasma renin activity  
increases due to removal of the angiotensin II feedback. 
Pharmacokinetics: 
                     Losartan is well absorbed following oral administration and undergoes significant  
first-pass metabolism to produce 5-carboxylic acid metabolite, designated as EXP3174. This  
metabolite is a long-acting (6 to 8 hr), noncompetitive antagonist at the AT1 receptor, and  
contributes to the pharmacological effects of losartan. EXP3174 is 10-40 times more potent 
 in blocking AT1 receptors than losartan. Losartan's bioavailability is about 32%. 
Metabolism is primarily by cytochrome P450 isoenzymes CYP2C9 and CYP3A4. Peak plasma  
concentrations of losartan and E-3174 occur about one hour and three to four hours, respectively,  
after an oral dose. Both losartan and E-3174 are more than 98% bound to plasma proteins.  
Losartan is excreted in the urine, and in the feces via bile, as unchanged drug and metabolites.  
About 4% of an oral dose is excreted unchanged in urine, and about 6% is excreted in urine as  
the active metabolite. The terminal elimination half lives of losartan and E-3174 are about 1.5 to  
2.5 hours and 3 to 9 hours, respectively. 
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5. EXCIPIENTS PROFILE 
6.1 Hydroxypropyl MethylCellulose117 
Synonyms: Hydroxypropylmethylcellulose;HPMC;Methocel;Benecel MHPC                                
                  methyl hydroxy propyl cellulose; methylcellulose propylene glycol ether; Metolose. 
 
 Structural formula:  
 
Figure: 7 Structure of HPMC 
Functional category: 
 Coating agent, film-former, rate-controlling polymer for sustained release, stabilizing 
agent, suspending agent, tablet binder, viscosity-increasing agent. 
Physicochemical Properties: 
Description                 :  White to off white powder, free flowing powder 
Particle size                    :  Minimum 95% through a #40 US standard sieve 
Methoxyl content             :  19-24% 
Hydroxypropyl content    :        7-12% 
Bulk density                    :  0.12 – 0.15 g/ml 
pH (1% content)           :  5.5-8 
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Solubility                         :  HPMC K100M is a high viscosity polymer which is   
                                                                                            soluble in water. 
Stability and storage:  
      Hypromellose powder is stable material, although it is hygroscopic after drying. 
Solutions are stable at PH 3-11. Increasing temperature reduces the viscosity of solutions. 
Hypromellose undergoes a reversible sol-gel transformation upon heating and cooling. The gel 
point is 50-900C, depending upon the grade and concentration of material. 
 Aqueous solutions are comparatively enzyme-resistant, providing good viscosity 
stability during long term storage. However, aqueous solutions are liable to microbial spoilage 
and should be preserved with an antimicrobial preservative. Aqueous solutions may also be 
sterilized by autoclaving; the coagulated polymer must be redispersed on cooling by shaking. 
Hypromellose powder should be stored in a well closed container, in a cool, dry place. 
Applications: 
              Hypromellose is primarily used as a tablet binder, in film coating, and as a matrix for 
use in extended-release tablet formulations. Concentrations between 2% and 5% w/w may be 
used as a binder in either wet- or dry-granulation process. High-viscosity grades may be used to 
retard the release of drugs from a matrix at levels of 10-80% w/w in tablets and capsules. 
Hypromellose is also used as suspending agent in topical formulations. Compared with methyl 
cellulose, hypromellose produces aqueous solutions of greater clarity, with fewer undispersed 
fiber present, and is therefore preferred in formulations for ophthalmic use. Hypromellose at 
concentrations between 0.45-1.0% w/w may be added as thickening agent to vehicles for eye 
drops and artificial tear solutions. 
          Hypromellose is also used as an emulsifier, suspending agent, and stabilizing agent in 
topical gels and ointments.  
 
                                                                                                                                               43 
6.2 Sodium Starch Glycolate118 
Synonyms: 
 Carboxymethyl starch, Explotab, Primojel. 
 
Functional Category: 
 Tablet and capsule disintegrant.  
 
Description: 
 It is white to off-white, odourless, tasteless, free-flowing powder. 
 
Solubility 
 It is practically insoluble in water; sparingly soluble in ethanol (95%). In water it 
swells upto 300 times its volume.  
 
Incompatibilities 
 Incompatible with ascorbic acid  
 
Stability and Storage 
 It is a stable material. It should be stored in a well closed container to protect from 
wide variations in humidity and temperature that may cause cracking. 
 
Safety 
 It is generally regarded as a non-toxic and non-irritant material. However, oral 
ingestion of large quantities may be harmful.  
 
Applications in Pharmaceutical Formulation and Technology: 
               As a disintegrant in tablet (wet granulation and direct compression) and capsule 
formulation in 2-8% concentration 
 
 
                                                                                                                                                        44 
6.3 Colloidal Silicone Dioxide (Aerosil)119 
Nonproprietary Names  
 BP : Colloidal anhydrous silica 
 PhEur : Silica colloidalis anhydrica 
 USPNF : Colloidal silicon dioxide 
 Synonyms : colloidal silica, fumed silica, light anhydrous silicic   acid,   
silicic   anhydride  and  silicon dioxide fumed 
 Chemical Name : Silica 
 Molecular Weight : 60.08 
 Structural Formula :     SiO2 
 
Functional Category:   
Adsorbent, anticaking agent,emulsion stabilizer, glidant,  suspending agent, tablet disintegrant, 
thermal stabilizer, and viscosity-increasing agent.  
 
Applications in Pharmaceutical Formulation or Technology  
 Colloidal silicon dioxide is widely used in pharmaceuticals, cosmetics, and food 
products. Its small particle size and large specific surface area gives desirable flow characteristics 
that are exploited to improve the flow properties of dry powders in a number of processes such as 
tabletting.  
 
Description  
 Colloidal silicon dioxide is submicroscopic fumed silica with a particle size of  about  
15  nm.  It  is  a  light,  loose,  bluish-white-colored,  odorless,  tasteless,  and non-gritty amorphous 
powder.  
 
Stability and Storage Conditions  
 Colloidal silicon dioxide is hygroscopic but adsorbs large quantities of water 
without liquefying. When used in aqueous systems at a pH 0-7.5, colloidal silicon dioxide is  
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effective in increasing the viscosity of a system. However, at a pH greater than 7.5 the viscosity-
increasing properties of colloidal silicon dioxide are reduced; and at a pH greater than 10.7 this 
ability is lost entirely since the silicon dioxide dissolves to form silicates. Colloidal silicon 
dioxide powder should be stored in a well-closed container. Some grades of colloidal silicon 
dioxide have hydrophobic surface treatments that greatly minimize their hygroscopicity.  
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6.4 Crospovidone120 
 
Non proprietary Names: 
                                          BP : Crospovidone, PhEur : Crospovidonum, USPNF : Crospovidone 
 
Synonyms :  
 
                      Crosspovidonum ; crospopharm ; croslinked  povidone; polyplasdone XL ; 
                                              
                      Polyvinyl polypyrrolidine. 
 
 
Chemical name : 1 – ethenyl – 2 - pyrrolidine homopolymer. 
 
Description: 
 
Crospovidone is a white to creamy-white, finely divided, free flowing, practically tasteless,  
odourless or nearly odourless, hygroscopic powder. 
 
Applications in Pharmaceutical Formulation: 
 
Crospovidone is a water-insoluble tablet disintegrant and dissolution agent used at 2-5%  
concentration in tablets prepared by direct compression or wet and dry-granulation methods. It is  
rapidly exhibits high capillary activity and pronounced hydration capacity, with little tendency to  
form gels. Larger particles provide a faster disintegration than smaller particles. Crospovidone  
can also be used  as a solubility enhancer. With the technique of co-evaporation, crospovidone  
can be used to enhance the solubility of poorly soluble drugs. 
Moisture Content : Maximum moisture sorption is approximately 60%. 
Solubility             : Practically insoluble in water and most common  organic solvents. 
 
Incompatibilities: 
 
Crospovidone is compatible with most organic and inorganic pharmaceutical ingredients. When  
exposed to a high water level, crospovidone may form molecular adduct with some materials like  
sulfathiazole, sodium salicylate, salicylic acid, Phenobarbital and tannin. 
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6.5 Micro Crystalline Cellulose121 
 
Non Proprietary Names: 
BP : Microcrystalline Cellulose 
JP : Microcrystalline Cellulose 
PhEur : Cellulose, Microcrystalline 
USP-NF : Microcrystalline Cellulose 
 
Synonyms :  
 
                        Avicel PH; Celex; Cellulose gel; hellulosum microcristallinum; Celphere;  
Ceolus  KG; crystalline cellulose; E460; Emcocel; ethispheres . 
 
Description : 
 
              Microcrystalline cellulose is a purified partially depolymerised cellulose that  
occurs as a white, odourless, tasteless, crystalline powder composed of porous particles. It 
is commercially available in different particle sizes and moisture grades that have different  
properties and applications. 
 
Chemical Name : cellulose 
 
Empirical Formula and Molecular Weight 
 
                                                                          (C6H10O5) n 36000 
                                                                              where n=220  
 
Functional Category : 
 
 Adsorbent; suspending agent; tablet and capsule diluents; tablet  disintegrant. 
 
Stability and Storage Conditions 
 
Microcrystalline cellulose is a stable through hygroscopic material. The bulk material should be  
stored in a well-closed container in a cool, dry place. 
 
Incompatibilities : Microcrystalline cellulose is a incompatible with strong oxidizing agents. 
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 Applications: 
 
Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a binder/diluents in  
oral tablet and capsule formulations where it is used in both wet granulation and direct- 
compression processes. In addition to its use as a binder/diluents, microcrystalline cellulose also  
has some lubricant and disintegrant properties that make it useful in tableting. 
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6.6 Starch122 
 
Nonproprietary Names 
 
Maize starch, Potato starch, Rice Starch, Tapioca Starch, Wheat Starch (BP, JP, PhEur, USP) 
 
Synonyms 
 
Amido, amidon, amilo, amylum, C*PharmGel, Eurylon, fecule, Hylon, maydis amylum, 
Melojel, Meritena, oryzae amylum, Pearl, Perfectamyl, pisi amylum, Pure-Dent, Purity 21, 
Purity 826, solani amylum, tritici amylum, Uni-Pure. 
Empirical Formula  :  (C6H10O5)n where n = 300–1000. 
Molecular Weight  :  50 - 500 million Da 
Structural Formula 
 
Description 
 
Starch occurs as an odorless and tasteless, fine, white to off-white powder. It consists of 
very small spherical or ovoid granules or grains whose size and shape are characteristic for each 
botanical variety. 
Typical Properties 
 
pH   :  4.0–8.0 
 
Moisture content: 
 
All starches are hygroscopic and absorb atmospheric moisture to reach the equilibrium 
humidity. The approximate equilibrium moisture is 12 – 18 % 
Solubility : 
Practically insoluble in cold ethanol (96%) and in cold water. Starch becomes soluble in 
hot water at temperatures above the gelatinization temperature. Starches are partially soluble in 
dimethylsulfoxide and dimethylformamide. 
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Functional Category: 
  Tablet and capsule diluent; tablet and capsule disintegrate; tablet binder; thickening 
 
   agent. 
 
Applications in Pharmaceutical Formulation or Technology: 
 
Starch act as an antiadherent and lubricant in tableting and capsule filling (3–10% 
w/w).In tablet formulations, freshly prepared starch paste is used at a concentration of 3–20% 
w/w (usually 5–10%, depending on the starch type) as a binder for wet granulation. Starch is one 
of the most commonly used tablet disintegrants at concentrations of 3–25% w/w;a typical 
concentration is 15%.Starch, particularly the fine powders of rice and wheat starch, is also used 
in topical preparations for its absorbency of liquids. Starch paste is used in ointment 
formulations, usually in the presence of higher ratios of glycerin. Starch has been investigated as 
an excipient in novel drug delivery systems for nasal, and other site-specific delivery systems 
(colon). They can improve the bioavailability of poorly soluble drugs. Starch has also been used 
in the treatment of children’s diarrheal diseases. Starches with a high amylopectin content (waxy 
starches) are used as the starting material for the synthesis of hydroxyethyl starch, a plasma 
volume expander. 
 
Stability and Storage Conditions: 
Dry starch is stable if protected from high humidity.Starch should be stored in an airtight 
container in a cool, dry place 
 
Incompatibilities: 
Starch is incompatible with strongly oxidizing substances. Colored inclusion compounds 
are formed with iodine. 
 
Safety: 
It is regarded as an essentially nontoxic and nonirritant material. Both amylose and 
amylopectin have been evaluated as safe and without limitation for daily intake. 
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6.7 Isopropyl Alcohol 123 
 
Nonproprietary Names: 
 
Isopropyl Alcohol (BP, JP, PhEur, USP) 
 
Synonyms: 
 
      Alcohol isopropylicus, dimethyl carbinol, IPA, isopropanol, petrohol, 2-propanol,  
 
      sec-propyl  
 
Chemical Name :  Propan-2-ol   
          
Empirical Formula :  C3H8O   
 
Molecular Weight : 60.1 
 
 
Structural Formula 
 
Description 
 
 
Isopropyl alcohol is a clear, colorless, mobile, volatile, flammable liquid with a 
characteristic, spirituous odor and it has a slightly bitter taste. 
Typical Properties 
 
Boiling point              :  82.40C 
 
Flammability           :  Flammable. 
 
Viscosity (dynamic)  : 2.43 mPas at 200C 
 
            Specific gravity         :  0.786 
 
Solubility  
 
Miscible with benzene, chloroform, ethanol (95%), ether, glycerin, and water. Soluble in 
acetone; insoluble in salt solutions.  
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Functional Category: Disinfectant, solvent. 
 
Applications in Pharmaceutical Formulation or Technology 
 
Isopropyl alcohol is also used as a solvent both for tablet film-coating and for tablet 
granulation, where the isopropyl alcohol is subsequently removed by evaporation. It has also 
been shown to significantly increase the skin permeability of nimesulide. Isopropyl alcohol has 
some antimicrobial activity and a 70% v/v aqueous solution is used as a topical disinfectant. 
Therapeutically, isopropyl alcohol has been investigated for the treatment of postoperative 
nausea or vomiting. 
Storage Conditions 
 
Isopropyl alcohol should be stored in an airtight container in a cool, dry place. 
 
Incompatibilities 
 
 Incompatible with oxidizing agents such as hydrogen peroxide and nitric acid,  
 
which cause decomposition.  
 
Safety: 
Isopropyl alcohol is most frequently used in topical pharmaceutical formulations where it 
may act as a local irritant. When applied to the eye it can cause corneal burns and eye damage. 
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6.8 Magnesium stearate124 
Description:  
                  It is a fine, white, precipitated or milled, impalpable powder of low bulk density, 
having a   faint odor of stearic acid and a characteristic taste. The powder is greasy to touch and 
readily adheres to the skin. 
Molecular weight  : 591.34 
Structural Formula  : [CH3 (CH2) 16 COO] 2 Mg   
Crystalline Forms : High purity magnesium stearate has been  
isolated as a trihydrate, a dihydrate, and an anhydrate. 
Flow ability   : Poorly flowing, cohesive powder. 
Melting range : 117-150 oC (commercial samples) 126-130 o C  
(high purity magnesium stearate) 
Solubility : Practically insoluble in ethanol, 
ether and water; slightly soluble in warm benzene and 
warm ethanol (95 %) 
Functional category  : Tablet and capsule, lubricant. 
Applications   : It is primarily used as a lubricant in capsule and  
tablet manufacture at concentrations between 0.25% and 
5.0 % w/w. 
Incompatibilities  : Incompatible with strong acids, alkalis, and iron  
salts. Strong oxidizing materials. Magnesium stearate 
cannot be used in products containing aspirin, some 
vitamins and most alkaloidal salts. 
Safety    : Oral consumption of large quantities may result  
                                                            in some laxative effect or mucosal irritation 
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6.9 Dibasic Calcium Phosphate125 
 
Nonproprietary Names 
 
BP: Calcium hydrogen phosphate 
JP: Dibasic calcium phosphate 
PhEur: Calcii hydrogenophosphas dihydricus 
USP: Dibasic calcium phosphate 
 
Synonyms 
 
Calcium hydrogen orthophosphate dihydrate; calcium monohydrogen phosphate dihydrate;  
Di-Cafos; dicalcium orthophosphate;DI-TAB; E341; Emcompress; phosphoric acid calcium salt  
(1 : 1) dihydrate; secondary calcium phosphate. 
 
 Chemical Name and CAS Registry Number 
 
Dibasic calcium phosphate dihydrate 
 
 Functional Category 
 
Tablet and capsule diluent. 
 
Applications in Pharmaceutical Formulation or Technology: 
 
Dibasic calcium phosphate dihydrate is widely used in tablet formulations both as an excipient  
and as a source of calcium and phosphorus in nutritional supplements.(1–8) It is one of the more 
 widely used materials, particularly in the nutritional/health food sectors. It is also used in  
pharmaceutical products because of its compaction properties, and the good flow properties of  
the coarse-grade material. The predominant deformation mechanism of dibasic calcium  
phosphate coarsegrade is brittle fracture and this reduces the strain-rate sensitivity of the  
material, thus allowing easier transition from the laboratory to production scale. However,  
dibasic calcium phosphate dihydrate is abrasive and a lubricant is required for tableting, for  
example about 1% w/w of magnesium stearate or about 1% w/w of sodium stearyl fumarate is  
commonly used. Two main particle-size grades of dibasic calcium phosphate 
dihydrate are used in the pharmaceutical industry. The milled  material is typically used in wet- 
granulated, roller-compacted or slugged formulations. The ‘unmilled’ or coarse-grade material is  
typically used in direct-compression formulations.Dibasic calcium phosphate dihydrate is non  
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hygroscopic and stable at room temperature. However, under certain conditions of temperature  
and humidity, it can lose water of crystallization below 1008C. This has implications for certain  
types of packaging and aqueous film coating since the loss of water of crystallization appears to  
be initiated by high humidity and by implication high moisture vapor concentrations in the  
vicinity of the dibasic calcium phosphate dihydrate particles.Dibasic calcium phosphate 
 dihydrate is also used in toothpasteand dentifrice formulations for its abrasive properties. 
 
Description: 
Dibasic calcium phosphate dihydrate is a white, odorless, tasteless powder or crystalline solid. It  
occurs as monoclinic crystals. 
 
 Stability and Storage Conditions 
Dibasic calcium phosphate dihydrate is a nonhygroscopic, relatively stable material. However,  
under certain conditions the dihydrate can lose water of crystallization. This has implications for  
both storage of the bulk material and coating and packaging of tablets containing dibasic calcium  
phosphate dihydrate.The bulk material should be stored in a well-closedcontainer in a cool, dry  
place. 
 
Handling Precautions 
Observe normal precautions appropriate to the circumstances and quantity of material handled.  
The fine-milled grades can generate nuisance dusts and the use of a respirator or dust mask may  
be necessary. 
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6.10 Starch, Pregelatinized126 
 
Nonproprietary Names 
 
BP: Pregelatinised starch 
 
PhEur: Amylum pregelificatum 
 
USPNF: Pregelatinized starch 
 
Synonyms 
 
Compressible starch; Instastarch; Lycatab C; Lycatab PGS;Merigel;  
 
 Functional Category 
 
Tablet and capsule diluent; tablet and capsule disintegrant;tablet binder. 
 
Applications in Pharmaceutical Formulation or Technology 
 
Pregelatinized starch is a modified starch used in oral capsule and tablet formulations as a binder,  
 
Diluent,and disintegrant.In comparison to starch, grades of pregelatinized starch may 
 
be produced with enhanced flow and compression characteristicssuch that the pregelatinized  
 
material may be used as atablet binder in dry-compression or direct compression 
 
processes.(4–14) In such processes, pregelatinized starch is self lubricating.However, when it is  
 
used with other excipients it may be necessary to add a lubricant to a formulation. Although 
 
magnesium stearate 0.25% w/w is commonly used for this purpose, concentrations greater than  
 
this may have adverse effects on tablet strength and dissolution. Therefore, stearic 
 
acid is generally the preferred lubricant with pregelatinized 
 
starch.Pregelatinized starch may also be used in wet granulation 
 
processes. 
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Description: 
 
Pregelatinized starch occurs as a moderately coarse to fine,white to off-white colored powder. It  
 
is odorless and has a slight characteristic taste.Examination of fully pregelatinized starch as a  
 
slurry in cold water, under a polarizing microscope, reveals no significant ungelatinized  
 
granules, i.e., no ‘maltese crosses’ characteristic of the starch birefringence pattern. Examination  
 
of samples suspended in glycerin shows characteristic forms depending upon the method of  
 
drying used during manufacture: either irregular chunks from drum drying or thin plates.  
 
Partially pregelatinized starch (e.g., Starch 1500G and Sepistab ST200) show retention of  
 
birefringence patterns typical of unmodified starch granules. 
 
Solubility: Practically insoluble in organic solvents. Slightly soluble to soluble in cold water,  
 
depending upon the degree of pregelatinization. Pastes can be prepared by sifting the 
 
pregelatinized starch into stirred, cold water. Cold-water soluble matter for partially  
 
pregelatinized starch is 10–20%. 
 
 Stability and Storage Conditions 
 
Pregelatinized starch is a stable but hygroscopic material, which should be stored in a well- 
 
closed container in a cool, dry place. 
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  6. MATERIALS AND METHODS 
 
 Table 4 : Materials used in the study 
Sl. No Materials 
 
Manufacturers/ suppliers 
1 Amlodipine besylate Arch Pharma labs 
2 Losartan potassium CPS Pharm labs  
3 Microcrystalline Cellulose RanQ Remedies, Mumbai. 
4 Sodium Starch Glycolate Dow Chemicals, Canada. 
        5 Starch Vijaya Enterprises, 
Mumbai. 
6 Crospovidone XL 10 Basf, Germany. 
7 Pregelatinised starch 
 
Vijaya Enterprises, 
Mumbai. 
8 Ponceau 4 R Lake Roha Dye Chem, Mumbai 
9 Quinoline yellow lake Roha Dye Chem, Mumbai 
10 Methylene chloride 
 
Gujarat Allealis & 
Chemicals 
11 Colloidal silicon dioxide    (Aerosil) 
 
Cobot Sanmar, USA. 
12 Instacoat Dow Chemicals, Canada 
13 Magnesium stearate 
 
Amshi Drug and 
Chemicals, Gujarat. 
14 Isopropyl alcohol Lee Changyung Chemicals. 
 
 
 
      
                                                                                                                                                                                                                  
.                                                                                                                                                                                      
 
 
 
 
 
                                                                                                                                                    59 
 
                Table 5: Manufacturing Equipments used in the study 
 
Sl. No Equipments Manufacturers/ Suppliers 
1 Moisture  balance Sartorius, Germany 
2 Vibratory sifter Bectochem, Mumbai. 
3 
Planetary Mixer (vertical 
main drive) 
Bectochem, Mumbai. 
4 Hexagonal blender Bectochem, Mumbai. 
5 Rapid mixer Granulator Bectochem, Mumbai. 
6 Fluidized bed dryer Bectochem, Mumbai. 
7 Tray drier Micro, S.B.Panchal and Co, India 
8 Multi Mill Bectochem, Mumbai. 
9 
Double Rotary Compression 
Machine (27 station) 
Cadmach, India. 
10 Dehumidifier Tropical nortec, India 
11 Vernier caliper Mitutoyo corps, Japan 
12 Blister Packing machine Lab module, India 
13 
Photostability and humidity 
chamber 
Thermolabs India Ltd. 
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Table 6: List of Instruments used in the study 
 
Sl. No Instruments Manufacturers/ Suppliers 
1 Electronic weighing balance Shimadzu corporation, Japan 
2 pH Meter Mettler, Toledo, India. 
3 Tap Density apparatus, ETD-1020 Electro lab, India. 
4 Hardness tester Monsanto , India 
5 Friability Test Apparatus, ET-2 Electro lab, India. 
6 Dissolution Apparatus, TDT-08L, Electro lab, India. 
7 Disintegration Apparatus Electro lab, India. 
8 FT-IR Spectrophotometer 8300 Shimadzu corporation, Japan 
9 Differential scanning colorimetry  DSC Q2000 V24.4 build 114  
10 
UV- Visible Spectrophotometer 
(UV-1601) 
Shimadzu corporation, Japan 
11 HPLC with PDA detector Waters HPLC, India. 
12 Refrigerator Whirlpool, India 
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Table 7: List of Reagents used in the study 
 
Sl. No Reagents/ chemicals  Manufacturers/suppliers 
1 
Potassium dihydrogen ortho 
phosphate AR 
 
Rankem, New Delhi. 
2 Sodium hydroxide AR  Rankem New Delhi. 
3 Acetonitrile HPLC  Merck Canada. 
4 Methanol HPLC  Merck, Canada. 
5 
Sodium dihydrogen ortho 
phosphate AR 
 
Rankem, New Delhi. 
6 Ortho phosphoric acid AR  Rankem, New Delhi. 
7 Hydrochloric acid AR  Rankem, New Delhi 
8 Whatman filter paper  Sartourious 292A, North America. 
9 0.45 µ filter paper  Millipore, Canada. 
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                                                   6. METHODS 
 
6.1 Preformulation studies 
 
6.1.1 Physicochemical Interaction of drug and polymer: 
Physicochemical Interaction of drug and excipients for amlodipine was done as per IP by 
the identification test carried out by the Fourier Transform Infra red spectrophotometer (FTIR) 
and the report was shown in figures 13-17. 
        Physicochemical Interaction of drug and excipients for losartan was done as per IP by the 
identification test carried out by the Fourier Transform Infra red spectrophotometer (FTIR) and 
the reports were shown in figures 13-17. 
 
6.1.2 Calibration curve of Amlodipine Besylate: 
 
 
100 mg  of  Amlodipine besylate  was accurately weighed and dissolved in 25 ml of 
methanol in  100ml volumetric flask and the volume was made up to the mark using 
methanol, to make  (1000 µg/ml) standard  stock  solution . Then 1 ml stock solution  was 
taken in another 100 ml volumetric flask and further diluted in 100 ml of methanol to make 
(10 µg/ml) standard stock solution, then  final concentrations  were  prepared  with 0.1N 
HCL.The absorbance of standard solution was determined using UV/VIS spectrophotometer at 
237nm. 
 
6.1.3 Calibration Curve of Losartan Potassium 
 
Accurately weighed 100mg Losartan Potassium was transferred into 100ml volumetric flask and 
dissolved in Small quantity of Methanol and the volume was made up with phosphate buffer pH  
6.8 to give a stock solution of concentration of 1mg/ml. Further dilutions were made in the  
range  of 2-20mcg/ml with phosphate buffer pH 6.8 and absorbance was measured at 235nm 
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6.2  Manufacturing process of Losartan Potassium and Amlodipine Besylate 
                                                                                                 Bilayer Tablets: 
 
 
     6.2.1  Losartan Part: 
 
 Sifting: 
Sift the weighed quantities of Losartan Potassium, Microcrystalline cellulose plain , starch 
plain and Polyplasdone XL10 through Mesh 30#. 
 
 Dry Mix and Granulation: 
Transfer the sifted materials and Binder solution to Granulation area. Load the sifted material 
into the main bowl of rapid mixer and mix it for 15 minutes  
 
 Initial Drying, Sifting and Milling: 
Transfer the sifted materials into FBD main bowl. Dry the granules at 50 degrees Celsius. Sift 
the Semi-Dried granules through Mesh 20# and pass the retained granules through Multi-Mill 
fitted with 1.0 mm screen using knives forward medium speed. 
 
 Final drying and shifting: 
Transfer the semidried sifted and milled granules into FBD bowl. Dry the semidried sifted 
granules at 50 degrees Celsius till the required LOD is achieved. Check the LOD of the 
granules (Limit: Between 2.0-4.0% w/w at 105 C ) 
 
 Lubrication: 
Sift the following materials Pregelatinised Starch, and Polyplasdone XL10 through Mesh 
30#.Load the sifted dried granules along with the above sifted materials into blender and 
blend it for 10 minutes. Finally sift Magnesium Stearate through Mesh 60#and mix for 5 
minutes. 
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Figure 8: Flow chart of Losartan Potassium Granules preparation 
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6.2.2 Amlodipine Part: 
 
 Sifting: 
Sift the weighed quantities of Amlodipine Besylate , Dicalcium Phosphate Anhydrous , 
Microcrystalline cellulose pH 102, starch 1500, sodium starch glycolate,colloidal silicon 
dioxide and pass through Mesh30#. Ponceau 4R Lake was passed through Mesh100# and 
added to the above blend. 
 
 Dry Mixing: 
Load the sifted materials such as Amlodipine Besylate, Dicalcium Phosphate Anhydrous, 
Microcrystalline cellulose pH 102, Starch 1500, Sodium Starch glycolate, colloidal silicon 
dioxide and Ponceau 4R Lake in Hexagonal blender and mix for 15 minutes 
 
 Lubrication: 
Sift Magnesium Stearate through Mesh60# and add to the above mixture in the blender and 
mix for  another  5 minutes. 
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Figure 9: Flow chart of Amlodipine Besylate Blend preparation:Direct Compression 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                  
 
 
 
Mixing(5Min) 
 
Amlodipine           
Besylate 
DCP,SSG,AEROSIL 
MCC Ph 102 
Starch 1500 
 
    30# Mesh 
  Hexagonal 
Blender(15 MINS) 
Magnesium Sterate 
           Ponceau 4R   
Lake   
 
   60# Mesh    100# Mesh 
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6.2.3 Compression of Bilayer tablets 
 
The quantity of granules for the immediate-release layer was compressed lightly using 
27 stationary double rotary compression machine (Cad mach, India) using 13/32 inch circular 
standard plain punches. Over this compressed layer, required quantity of the other immediate 
release layer was placed and compressed to obtain hardness in the range of 8-12 kg/cm² to 
form a bilayer tablet of Immediate release of Losartan potassium  and Immediate release of 
Amlodipine besylate. Then the compressed bilayer tablets were evaluated.  
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Figure 10: Flowchart of Bilayer Tablets of Amlodipine Besylate and Losartan 
                                                                                          Potassium Preparation 
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Table 8:Losartan Potassium  Layer Trials 
INGREDIENTS 
 
L1 
(Mg/tab) 
L2 
(Mg/tab) 
L3 
(Mg/tab) 
L4 
(Mg/tab) 
L5 
(Mg/tab) 
L6 
(Mg/tab) 
L7 
(Mg/tab) 
L8 
(Mg/tab) 
Losartan Potassium 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 
MCC Plain 175.50 165.50 148.50 139.00 127.50 110.50 104.00 95.00 
Starch Plain        
- 
   10.00   10.00    15.00   15.00    25.00   25.00 30.00 
Crospovidone XL 
10 
- -    5.00  
5.00 
 7.00  7.00  9.00   11.00 
P.Water(For  
Granulation) 
q.s q.s q.s q.s q.s q.s q.s q.s 
 
                                                                             LUBRICATION 
Pregelatinised 
starch 
- -   7.50   7.50   15.00   20.00   22.50 22.50 
Crospovidone XL 
10 
- -   4.50   9.00   11.00   13.00   15.00 17.00 
Magnesium 
Stearate 
4.50   4.50   4.50   4.50   4.50   4.50   4.50 4.50 
Total Weight 230.00 230.00 230.00 230.00 230.00 230.00 230.00 230.00 
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Table 9: Amlodipine besylate layer trials 
 
 
Ingredients 
 
A1 
(Mg/tab) 
A2 
(Mg/tab) 
A3 
(Mg/tab) 
A4 
(Mg/tab) 
A5 
(Mg/tab) 
A6 
(Mg/tab) 
Amlodipine 
Besylate 
7.00 7.00 7.00 7.00 7.00 7.00 
DCP 
 
45.00 43.00 43.00 42.00 42.00 40.00 
MCC pH102 
 
65.0 65.00 62.00 62.00 57.00 58.00 
Pregelatinised 
Starch  
- 2.00 4.00 4.00 8.00 8.00 
SSG 
 
- - 1.00 2.00 3.00 4.00 
Aerosil 
 
1.00 1.00 1.00 1.00 1.00 1.00 
Ponceau4R Lake 
 
1.00 1.00 1.00 1.00 1.00 1.00 
Magnesium 
Stearate 
1.00 1.00 1.00 1.00 1.00 1.00 
Total weight 
 
120 120 120 120 120 120 
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Table 10: Formulation Trials of Bilayer tablets 
 
Ingredients F-1 
(Mg/tab) 
F-2 
(Mg/tab) 
F-3 
(Mg/tab) 
F-4 
(Mg/tab) 
F-5 
(Mg/tab) 
F-6 
(Mg/tab) 
F-7 
(Mg/tab) 
F-8 
(Mg/tab) 
Losartan Layer 
Losartan 
Potassium 
50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 
MCC Plain 175.50 
 
165.50 148.50 139.00 127.50 110.50 104.00 95.00 
Starch Plain - 10.00 10.00 15.00 15.00 25.00 25.00 30.00 
 
Crospovidone 
XL 10 
- - 5.00 5.00 7.00 7.00 9.00 11.00 
P.Water(For  
Granulation) 
   q.s     q.s     
q.s 
 q.s q.s  q.s  q.s    q.s 
LUBRICATION 
Pregelatinised 
starch 
- - 7.50 7.50 15.00 20.00 22.50 22.50 
Crospovidone 
XL 10 
- - 4.50 9.00  11.00  13.00  15.00 17.00 
Magnesium 
Stearate 
    4.50    4.50 4.50 4.50   4.50   4.50   4.50 4.50 
 Amlodipine Layer 
Amlodipine 
Besylate 
7.00 7.00 7.00 7.00 7.00 7.00 7.00 7.00 
DCP 
 
45.00 43.00 43.00 42.00 42.00 40.00 40.00 40.00 
MCC pH102 
 
65.0 65.00 62.00 62.00 57.00 58.00 58.00 58.00 
Pregelatinised 
Starch  
- 2.00 4.00 4.00 8.00 8.00 8.00 8.00 
SSG 
 
- - 1.00 2.00 3.00 4.00 4.00 4.00 
Aerosil 
 
1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Ponceau 4R 
Lake 
1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Magnesium 
Stearate 
1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Total weight 
 
350 350 350 350 350 350 350 350 
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6.3 Evaluation of Granules. 
 
6.3.1 Bulk density 127: 
 
Bulk density is the ratio of the weight of the powder to the bulk volume it occupies. it is 
expressed in gm/ml. A weighed  quantity  of  powder  blend  previously  shaken  to  break  
any agglomerates formed, was introduced in to a measuring cylinder and the volume was 
noted.   
Bulk density was calculated using the following equation; 
            Bulk density   =               Mass of the powder Blend taken 
                                               Volume occupied by the powder blend 
   
 
6.3.2 Tapped density127: 
 
 
A weighed  quantity  of  powder  blend  previously  shaken  to  break  any  agglomerates 
formed, was  introduced in to a measuring cylinder and the volume was noted. The 
cylinder was placed in the tapped density apparatus and allowed to fall under its own 
weight on to a  hard surface (USP-II), that provides fixed a drop of 3mm(±10%) at a 
nominal rate of 250 drops per  minute is used. Tapping was continued until no further 
change in volume was noted.  Td was calculated using the following equation; 
 
                  Tapped density=           Mass of the powder Blend taken 
                                               Tapped Volume of the powder blend 
 
 
6.3.3 Carr’s Index127: 
 
Carrs Index is an important measure that can be obtained from the bulk and tapped 
densities. In theory, the less compressible a material the more flow able it is. A material 
having values of less than 20 is defined as the free flowing material.48 The formula for 
Carrs Index is as below: 
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         Carrs Index  (%)     = 100       1 -   Bd 
 
                                                           Td 
 
 
 
                             Table 11: Carr’s index values and type of flow 
Carr’s index Type of flow 
5-15 Excellent 
12-15 Good 
18-21 Fair 
23-30 Poor 
33-38 Very poor 
>40 Extremely poor 
 
 
 
6.3.4 Hausner’s ratio127: 
 
        It indicates the flow properties of the powder and is measured by the ratio of 
tapped        
        density to the bulk density 
 
         Hausners ratio = (Tapped density)/ (Bulk density) 
 
 
                   Table 12:   Hausners ratio and flow characters 
Flow characters Hausner ratio 
Excellent 1.11 
Good 1.12 – 1.18 
Fair 1.19 – 1.25 
Passable 1.26 – 1.34 
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   6.3.5 Angle of repose127: 
 
 
Angle  of  Repose  is  an  indication  of  the  frictional  forces  existing  between 
granule particles. The maximum angle possible between the surface of the pile of 
granules and the horizontal plane gives the angle of repose: 
 
tan θ = h / 
r 
 
Where, θ is the angle of repose; h is the height of the heap of powder and r is the 
radius of the heap of the powder. Therefore θ = tan-1 (h/r). 
 
Method: Weighed quantity of granules were poured through the funnel from the 
     fixed height  on the graph paper.  Then circumference of the heap was marked by 
       pencil. The radius of the circle formed was measured and angle of repose  
       then calculated on the parameter found out from the radius of circle and  
       height of the heap. 
 
                      Table 13: Angle of repose values and type of 
flow 
 
Poor 1.35 – 1.45 
Very poor 1.46 – 1.59 
 
Very Very poor >1.60 
 
Angle of repose(θ) Type of flow 
<25 Excellent 
25-30 Good 
30-40 Passable 
>40 Very poor 
 
 
 
6.3.6 Moisture content: 
 
Initially 5 g of weighed granules were taken and kept for drying at 1050 C for a 
required time in a oven. Then removed and again reweighed and noted as final weight. The 
difference in weight was noted as moisture content. 
        Moisture content      =    Initial weight – Final weight     ×   100 
                                                           Initial weight              
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6.4 EVALUATION OF TABLETS: 
 
6.4.1 Evaluation of physical characteristics 
  
The formulated tablets were evaluated for the following physical parameters, 
 
6.4.2 Thickness: 
 
          Thickness depends on die filling, physical properties of material to be compressed. 
There is possibility of small variation in the thickness of individual tablet in a batch. But it 
should not be apparent to the unaided eye. The thickness and diameter can be measured by 
vernier calipers.  
 
6.4.3 Hardness: 
 
Tablet must possess sufficient strength or hardness and can be measured by Monsanto 
hardness tester. Ten tablets were randomly picked from each formulation and were evaluated 
for hardness  and can be expressed in Kg/cm2 . 
 
6.4.4 Friability: 
 
Friability can be performed in Roche friabilator, Preweighed ten tablets were 
introduced in the friabilator. Then the machine was operated for 100 revolutions. Tablets were 
dropping from a distance of six inches with each revolution. Tablets were then dusted and 
reweighed. Loss of less than 1% in weight is considered to be within the specifications and 
acceptable.  
 
                         Initial wt. – Final wt.                                                
                                 Initial wt.   
 
6.4.5 Weight variation test128: 
 
Twenty tablets were selected randomly and weighed individually. Calculate average 
weight and compare the individual tablet weight to the average. Not more than two of the 
individual weights deviate from the average weight by more than the percentage shown in 
table and none deviate by more than twice the percentage.  
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Table 14: IP Specifications for weight variation 
Average weight of tablet (mg) Percentage difference allowed 
  
80 mg or less 10 
  
More than 80 mg but less that 250 mg 7.5 
  
250 mg or more 5 
  
 
6.4.6 Disintegration Time128 
 
The in-vitro disintegration time was determined by using disintegration test 
F (%) =  
+= 
× 100 
apparatus. One tablet was placed in each of the six tubes of the apparatus and one disc was 
added to each tube. The time in seconds taken for complete disintegration of the tablet with no 
palpable mass in the apparatus was measured in seconds. 
 
6.4.7 Drug content:Assay: (BY HPLC) 
For Amlodipine Besylate and Losartan Potassium 
 
Procedure: 
Chromatographic System 
Column                                : Inertsil  ODS C8 25×4.9mm 
Column temperature            : Ambient 
Flow rate                              : 1.0 ml / minute 
Injection volume                  : 20 l. 
Detector Wave length           : 237 nm    
Run Time                              : 25 minutes. 
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Diluent                                  : Buffer:Methanol:ACN(55:18:12). 
Instrument set up                  : isocratic 
Type of detector                    : UV 
 
Buffer 
 Dissolve 0.68g of potassium di hydrogen phosphate in 1000 ml of water,add 4ml 
of tryethylamine and adjust the pH to 5.0 with OPA 
Mobile Phase preparation: 
 Mix 850 ml of buffer, 75 ml of methanol and 75 ml of acetonitrile  
Standard Preparation 
 Weigh accurately 40mg of Amlodipine from amlodipine besylate working 
standard  and transfer into a 100 ml volumetric flask, dissolve and dilute to volume with 
mobile phase(Solution A) .40mg of losartan potassium was weighed transferred into standard 
volumetric flask and 10ml of solution A was added and the volume was made up with the 
mobile phase 
Sample  Preparation 
 10 tablets were randomly selected from collected samples of analysis, Powdered 
and transferred into 250ml standard flask. 170ml of mobile phase was added in the flask, 
dissolved and sonicated for 30mins and diluted to the volume with the mobile phase. 5ml of 
the above solution was transferred to 25ml standard flask and volume was made to 25ml. 
Procedure 
 Inject 20 µL portion of diluent as blank ,6 replicate injections of standard 
preparation and one injection of each test preparation into the HPLC system ,record the 
chromatograms and measure the peaks response. 
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Calculation: 
 
For Amlodipine Besylate 
  
  Spl Area            Std. wt       10       250        25         Purity    Avg wt {100-LOD} 
=  ------------ X ------------X ------X----------X ------X--------- X---------X--------------- XC.F 
  Std Area             100           100     Spl wt     5          100         1              100 
 
 
For Losartan Potassium 
 
    Spl Area         Std. wt         100          25        Avg wt      Purity          {100-LOD} 
=  ------------- X ------------X ----------X ------ X ----------X--------------- X--------------- 
  Std Area             100           Spl wt       5              1              100                 100   
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6.4.8 In vitro Dissolution studies: 
 
Procedure of Dissolution of bilayer tablets: 
 
Six tablets of Amlodipine Besylate  and Losartan Potassium (Bilayer tablets) were 
introduced in the dissolution apparatus USP Type II (paddle). The medium  used was  900 ml 
of 0.01 M sodium acetate buffer, pH 4.5 maintained with glacial acetic acid  and the 
dissolution mediums were maintained at the temperature of 37.5± 0.50 C, the RPM was set at 
75. The Dissolution was carried out for 30 minutes and sample withdrawn at predetermined 
intervals . The estimation was carried out by HPLC method. The optimized  formulation was 
compared with the market product. 
 
Estimation of Amlodipine by HPLC: 
Chromatographic system: 
 
Apparatus                 : HPLC, PDA Detector 
Column           : Inertsil ODS C8, 250× 4.6 mm 
Wave length    : 237 nm 
Injection volume : 50 µl 
Flow rate         : 1.0 ml/min 
Column Temperature : Ambient 
Diluent   : Dissolution medium 
Mobile phase             : Buffer:Methanol:ACN (55:18:22) 
Retention time            : 15 minutes 
Instrument set up       : Isocratic 
 
Standard preparation: 
 
Accurately 75.3mg of Amlodipine besylate was taken in 100ml of volumetric flask 
and 25ml of diluents were added and sonicated to dissolve and the volume was made up with 
diluents to 100ml. From this 10ml was pipetted out in to 100ml volumetric flask and volume 
was made with a diluents. From the above solution another 10 ml withdrawn and made upto 
100 ml and  Filtered through 0.45 micron membrane filter. 
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 Sample preparation: 
The dissolution parameters were set and one tablet is placed in each basket and care was taken 
to exclude air bubbles from the surface of the tablets and immediately the apparatus was 
started, 10ml of the sample was withdrawn and filter through whatmann filter paper, 10ml of 
solution was replaced in to dissolution medium, the same procedure was repeated at other 
time intervals. 
 Procedure: 
 
50 micro liters of filtered portion of the standard and sample solution was injected in 
to HPLC system. The chromatogram was recorded and responses were measured for major 
peaks. The % release of Amlodipine besylate was calculated by using following expression. 
 
Calculation for Amlodipine Besylate: 
 
    Spl Area    Std. wt    10      10        900    100       Purity   100-LOD 
=  -----------X ---------X-----x------x---------X------ X ------- X-------------X Conversion 
   Std Area     100         100    100       1         LC       100         100            Factor 
 
 
Conversion Factor: 
 
Molecular weight of Amlodipine besylate =567.10 
 
Molecular weight of Amlodipine               =410.10 
 
Conversion factor to convert amlodipine besylate to amlodipine(pure)= 410.10 
                                                                                                                 ---------- = 0.721 
                                                                                                                  567.10 
 
 
 
 
 
 
 
 
 
                                                                                                                                                        
81 
Estimation of Losartan by HPLC: 
 
Chromatographic system: 
Apparatus       : HPLC, PDA Detector 
Column           : Inertsil ODS C8, 250× 4.6 mm, 5µ 
Wave length    : 237 nm 
Injection volume : 50 µl 
Flow rate         : 1.0 ml/min 
Column Temperature : Ambient 
Diluents   : Acetonitrile and Dissolution medium 
Mobile phase  : Buffer:Methanol:ACN (55:18:22) 
 
Standard preparation: 
 
Accurately weighed 56.9mg of Losartan Potassium was taken in 100ml volumetric 
flask and 50ml of diluents and volume was made up by the diluents to 100ml. From this 10ml 
was pipetted out in to 100ml volumetric flask and volume was made up with dissolution 
medium. 
 
Sample preparation 
 
The dissolution parameters were set and one tablet was placed in to each basket care 
was taken to exclude air bubbles from the surface of the tablets and immediately the apparatus 
was started, 10ml of the sample was withdrawn and filter through whatmann filter paper, 
10ml of solution was replaced in to dissolution medium, the same procedure was repeated at 
other time intervals. 
 
Procedure 
50 micro liters of filtered portion of the standard and sample solution was injected in 
to HPLC system. The chromatogram was recorded and the responses were measured for the 
major peaks. The % release of Losartan Potassium was calculated an calculated and followed 
by the expression.   
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   Calculation for Losartan Potassium 
 
    Spl Area      Std. wt        10       900       100    Purity    100-LOD 
=  -----------X ------------X ------X------ X -------x------- X-------------- 
     Std Area      100            100      1           LC      100          100 
 
 
 
6.5 Coating of bilayered tablets:  
 
                Table 15: Coating solution composition: 
 
Ingredients Quantity for 1000 
tablets in grams 
Insta coat 10.5 
Quinoline yellow lake 0.75 
Iso propyl alcohol 117.50 
Methylene chloride 97.94 
 
      Instacoat: percentage of solution-5.25% w/w 
 
 
  6.5.1Film coating solution preparation: 
 
Isopropyl alcohol was transferred into a clean stainless steel vessel. Instacoat (IC-S-10) 
was  
added to the part of isopropyl alcohol. To the another part of isopropyl alcohol, quinoline  
yellow lake was added and was passed through the colloidal mill and mixed with the above  
solution. Finally methylene chloride was added to the above solution with continuous  
stirring. Care was taken that there were no lumps formation in the solution visually.  The  
above solution was filtered through mesh 100# nylon cloth. The above solution was  
transferred into a SS vessel of pressure vessel fitted with stirrer.  
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                       Table 16: Coating process specifications: 
 
 
 
 
 
 
 
 
 
 
                                               
 
                       
                        Table 17: Specifications of coating solution: 
 
S.No Parameters Limits 
1. Uniformity of colour NA 
2. Viscosity 600-700cps 
3. Weight gain 3% 
4. Percent solid content 5%w/v 
5. Microbial load NA 
 
 
                           Table 18: Coating tablet specifications: 
 
S.No Parameters Limits 
1. Description Yellow colour, circular shaped,plain 
surface film coating tablet 
2. Theoretical average weight 360mg±3% 
3. Uniformity of weight 360mg±5% 
4. Thickness 4.25-4.30mm 
5. Disintegration time NMT 30 minutes 
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S.No Parameters  Limits  
1. Pan speed 4 to 5 rpm 
2. Temperature   
 Inlet 45  c 
Outlet 40 c(±2 c) 
3. Gun operating pressure NLT 4kg/cm2 
4. Atomizing air pressure 3 – 4.5 kg/cm2 
5. Spray rate 100-150ml/min 
6. Drying time  
6.6 Stability Studies129. 
 
The stability studies were carried out according to ICH to assess the drug formulation 
stability. Optimized F8 formulation was sealed in aluminium packaging laminated with 
polyethylene. Sample were kept at 40⁰C and 75% RH for 1,2,3,6 months. At the end of the 
study period, the formulation was observed for change in physical appearance, color, drug 
content and drug release characteristics. The values were showed in the Table No.37. 
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7. Results 
 
 
     7.1 Calibration Curves 
 
             Table 19: Calibration Curve of Amlodipine Besylate 
                    Calibration Curve of Amlodipine Besylate 
S.NO Concentration(mcg/ml) Absorbance 
1 2 0.072 
2 4                  0.149 
3 6 0.211 
4 8 0.270 
5 10 0.346 
6 12 0.410 
7 14 0.466 
8 16 0.523 
9 18 0.597 
10 20 0.647 
 
 
 
    Figure 11: Calibration Curve of Amlodipine Besylate 
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y = 0.0323x + 0.0125
R² = 0.9986
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           Table 20: Calibration Curve of Losartan Potassium 
 
          Calibration Curve of Losartan Potassium 
S.NO Concentration (Mcg/ml)    Absorbance 
1. 2 
 
0.122 
2. 4 
 
0.209 
3. 6 
 
0.341 
4. 8 
 
0.483 
5. 10 
 
0.555 
6. 12 
 
0.625 
7. 14 
 
0.751 
8. 16 
 
0.814 
9. 18 
 
0.888 
10. 20 
 
0.960 
 
 
 
 
   Figure 12:Calibration Curve of Losartan Potassium 
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7.2 Preformulation Studies: 
 
Physicochemical Interaction of drug and excipients: 
 
 
 
 
 
Figure 13: IR spectra of Amlodipine Besylate (pure drug) 
 
 
 
 
 
 
 
 
Figure 14: IR Spectra of Losartan Potassium(Pure drug) 
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mit 1_1_1_1
Name
Sample 019 By organic Date Monday, February 18 2013
Description
4000 4503500 3000 2500 2000 1500 1000 500
102
10
20
30
40
50
60
70
80
90
100
cm-1
%
T
1192.16cm-1
1115.45cm-11487.24cm-1
1668.40cm-1
3158.79cm-1
3290.54cm-1 2971.75cm-1
736.25cm-1
597.83cm-1
2036.60cm-1
mit 2_1_1_1
Name
Sample 020 By organic Date Monday, February 18 2013
Description
4000 4503500 3000 2500 2000 1500 1000 500
102
10
20
30
40
50
60
70
80
90
100
cm-1
%
T
1192.10cm-1
1618.78cm-1 1114.85cm-1
1486.86cm-1
3162.79cm-1
3297.32cm-1
2969.83cm-1
736.76cm-1
602.57cm-1
2040.42cm-1
 
 
 
   Figure 15: IR spectra of Optimized Amlodipine Besylate Layer (A6)  
 
 
 
 
 
 
 
 
 
 
 
Figure 16: IR Spectra of Optimized Losartan Potassium Layer(L8) 
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mit 3_1_1_1
Name
Sample 021 By organic Date Monday, February 18 2013
Description
4000 4503500 3000 2500 2000 1500 1000 500
96
3
10
20
30
40
50
60
70
80
90
cm-1
%
T
1593.34cm-1
1445.06cm-1 1022.68cm-1
2920.68cm-1
1293.71cm-1
3230.19cm-1
718.83cm-1
2169.09cm-1
 
 
Figure 17: IR spectra of Optimized Coated Bilayer Formulation 
 
 
 
 
 
Table 21:IR Interpretations for Pure drug 
 
S.No Functional groups Characteristic peaks 
 cm-1 
Observed peaks 
 cm-1     
Amlodipine 
Observed peaks  
cm-1       Losartan 
1 OH 3100 - 3162.79 
2 N-H 3500-3100 3230.19 - 
3 C=0 1740 1687.41 1665.69 
4 Aromatic C-H 3100 2971.75 3162.43 
5 C-0 1300-1100 1116.92 - 
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7.3 Precompression parameters: 
 
Table 22:Precompression parameters for Amlodipine layer blend  
 
 
FORMULATION BULK 
DENSITY 
(g/ml) 
TAPPED 
DENSITY 
(g/ml) 
HAUSNER’S 
RATIO 
CARR’S 
INDEX 
(%) 
ANGLE OF 
REPOSE 
(θ) 
A1 0.634±0.002 0.740±0.001 1.16±0.01 14.32±0.65 26.3º±0.98 
A2 0.623±0.001 0.754±0.003 1.21±0.01 17.37±0.87 29.8 º±1.17 
A3 0.578±0.002 0.722±0.004 1.25±0.03 19.94±1.11 28.8 º±0.75 
A4 0.595±0.004 0.758±0.002 1.27±0.01 21.20±0.87 28.6 º±0.88 
A5 0.589±0.001 0.737±0.002 1.25±0.02 20.08±0.45 28.4 º±1.24 
A6 0.613±0.003 0.766±0.003 1.24±0.02 19.73±0.72 29.4 º±1.32 
 
 
 
Table 23:Precompression parameters for Losartan layer blend 
 
 
FORMULATION BULK 
DENSITY 
(g/ml) 
TAPPED 
DENSITY 
(g/ml) 
HAUSNER’S 
RATIO 
CARR’S 
INDEX 
(%) 
ANGLE 
OF 
REPOSE 
(θ) 
MOISTURE 
CONTENT 
(%) 
L1 0.488±0.002 0.605±0.002 1.17±0.01 19.39±0.89 30.4 º±1.40 4.3±0.2 
L2 0.479±0.003 0.604±0.006 1.25±0.01 20.60±1.12 31.7 º±1.23 4.4±0.2 
L3 0.491±0.001 0.617±0.001 1.26±0.03 20.89±1.45 32.5 º±0.95 4.5±0.1 
L4 0.487±0.002 0.612±0.002 1.25±0.01 20.41±1.23 31.8 º±0.89 4.2±0.2 
L5 0.490±0.007 0.599±0.002 1.09±0.02 18.19±1.16 26.2 º±1.15 4.5±0.1 
L6 0.479±0.008 0.605±0.001 1.26±0.01 20.82±1.31 29.9 º±1.63 4.1±0.2 
L7 0.486±0.009 0.609±0.003 1.25±0.02 20.32±0.93 29.4 º±1.34 4.3±0.1 
L8 0.477±0.005 0.600±0.004 1.25±0.02 20.51±0.96 30.3 º±0.90 4.2±0.1 
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7.4 Post compression parameters: 
 
 
 Table 24 :Post compression parameters for core bilayer tablets. 
 
BATCH THICKNESS 
(mm) 
 
HARDNESS 
(kg/cm2) 
FRIABILITY 
      % 
DISENTEGRATION  
TIME(MINUTES) 
F-1 4.09±0.011 6.4±0.57 0.22 11m 53s 
F-2 4.21±0.015 7.3±0.73 0.19 9m 14s 
F-3 4.32±0.014 7.8±0.34 0.13 7m 40s 
F-4 4.28±0.012 8.9±0.69 0.09 7m 47s 
F-5 4.24±0.011 8.5±0.76 0.15 6m 18s 
F-6 4.35±0.010 6.4±0.43 0.22 6m 41s 
F-7 4.26±0.011 7.9±0.67 0.18 6m 25s 
F-8 4.19±0.013 8.8±0.82 0.17 5m 30s 
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 Table 25: Post  compression parameters for coated tablets. 
 
BATCH THICKNESS 
(mm) 
 
DISENTEGRATION  
TIME(Minutes) 
ASSAY 
% 
F-1 4.21±0.011 10m 35s (A)-92.32 
(L)-97.34 
F-2 4.30±0.012 10m 28s (A)-91.66 
(L)-98.15 
F-3 4.43±0.015 8m 57s (A)-90.78 
(L)-97.56 
F-4 4.39±0.014 8m 42s (A)-94.98 
(L)-96.87 
F-5 4.34±0.017 7m 25s (A)-93.71 
(L)-97.87 
F-6 4.46±0.012 7m 32s (A)-92.45 
(L)-94.79 
F-7 4.37±0.011 6m 44s (A)-94.06 
(L)-95.50 
F-8 4.31±0.014 6m 45s (A)-94.70 
 (L)-96.87 
 
 
 
Table 26: Weight Variation Test 
BATCH F1 F2 F3 F4 F5 F6 F7 F8 
AVG WT 
(20 TAB) 
362±0.71 371±0.84 364±0.71 369±0.78 358±0.63 365±0.82 370±0.68  363±0.69 
% max 
positive 
deviation 
 
+1.98 +3.23 +2.76 +1.98 +2.41 +3.14 +2.23 +2.65 
% min 
negative 
deviation 
 
-1.34 -2.75 -1.87 -2.75 -2.63 -2.25 -1.87 -1.98 
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Model Chromatograms: 
Figure 18:Assay Diluent 
 
Figure 19:Assay Sample 
 
Figure 20:Assay Standard 
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7.5 In vitro dissolution studies 
Table 27 : In vitro dissolution profile of Bilayer tablet F-1  
                              
Immediate Release Layer of Amlodipine Besylate 
 
S.NO Time 
(mins) 
    Amount of drug release 
                 (mg) 
Cumulative Drug release 
 (%) 
1. 5 1.15±0.08 24.63 
2. 10 1.98±0.13 42.40 
3. 15 2.43±0.19 52.13 
4. 20 2.86±0.24 61.36 
5. 25 3.22±0.16 68.67 
6. 30 3.46±0.21 73.62 
                             
 Immediate Release Layer of Losartan Potassium 
 
S.NO 
 
Time 
(mins) 
     Amount of drug release 
               (mg) 
Cumulative Drug release 
(%) 
1. 5 10.24±0.21 21.12 
2. 10 17.67±0.43 36.54 
3. 15 24.01±0.24 49.60 
4. 20 27.42±0.36 56.65 
5. 25 30.41±0.87 62.81 
6. 30 33.12±0.67 68.40 
 
 
Figure 21:   In vitro Dissolution Profile of Formulation F-1  
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Table 28:In vitro dissolution profile of Bilayer tablet F-2 
                              
Immediate Release Layer of Amlodipine Besylate 
 
S.NO Time 
(mins) 
    Amount of drug release 
                  (mg) 
Cumulative Drug  release 
                (%) 
1. 5 1.85±0.14 39.50 
2. 10 2.51±0.11 53.73 
3. 15 2.80±0.23 59.98 
4. 20 3.16±0.19 67.78 
5. 25 3.42±0.12 73.31 
6. 30 3.57±0.15 76.15 
                             
 Immediate Release Layer of Losartan Potassium 
 
S.NO 
 
Time 
(mins) 
     Amount of drug release 
                 (mg) 
Cumulative Drug release 
                 (%) 
1. 5 12.78±0.24 26.36 
2. 10 19.34±0.33 39.93 
3. 15 28.15±0.28 58.12 
4. 20 31.35±0.56 64.73 
5. 25 33.85±0.75 69.88 
6. 30 34.99±0.56 72.25 
 
 
 
        
  Figure 22:   In vitro Dissolution Profile of Formulation F-2 
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Table 29: In vitro dissolution profile of Bilayer tablet F-3 
                              
Immediate Release Layer of Amlodipine Besylate 
 
S.NO Time 
(mins) 
    Amount of drug release 
                 (mg) 
Cumulative Drug release 
                (%) 
1. 5 2.37±0.16 50.60 
2. 10 2.68±0.10 57.42 
3. 15 2.99±0.21 64.54 
4. 20 3.21±0.11 68.91 
5. 25 3.46±0.15 74.23 
6. 30 3.71±0.19 79.71 
                             
 Immediate Release Layer of Losartan Potassium 
 
S.NO 
 
Time 
(mins) 
    Amount of drug release 
                 (mg) 
 Cumulative Drug release 
                (%) 
1. 5 18.45±0.23 38.05 
2. 10 25.38±0.54 52.38 
3. 15 32.39±0.87 66.85 
4. 20 35.61±0.75 73.50 
5. 25 36.25±0.39 74.81 
6. 30 37.60±0.81 77.59 
 
 
Figure 23:   In vitro Dissolution Profile of Formulation F-3 
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Table 30 :In vitro dissolution profile of Bilayer tablet F-4 
                              
Immediate Release Layer of Amlodipine Besylate 
 
S.NO Time 
(mins) 
Amount of drug release 
               (mg) 
 Cumulative Drug  release 
                 (%) 
1. 5 2.62±0.09 55.87 
2. 10 3.01±0.16 64.12 
3. 15 3.33±0.14 71.26 
4. 20 3.60±0.11 77.10 
5. 25 3.78±0.10 80.90 
6. 30 3.83±0.25 82.23 
                             
 Immediate Release Layer of Losartan Potassium 
 
S.NO 
 
Time 
(mins) 
Amount of drug release 
               (mg) 
 Cumulative Drug release 
                (%) 
1. 5 22.12±0.56 45.67 
2. 10 30.04±0.41 61.95 
3. 15 35.78±0.67 73.82 
4. 20 37.63±0.78 77.65 
5. 25 38.77±0.39 80.03 
6. 30 38.90±0.61 80.29 
 
 
 
Figure 24: In vitro Dissolution Profile of Formulation F-4 
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Table 31: In vitro dissolution profile of Bilayer tablet F-5 
                              
Immediate Release Layer of Amlodipine Besylate 
 
S.NO Time 
(mins) 
Amount of drug release 
               (mg) 
 Cumulative Drug  release 
                (%) 
1. 5 3.39±0.10 72.13 
2. 10 3.71±0.08 78.97 
3. 15 3.85±0.12 82.13 
4. 20 3.91±0.15 83.42 
5. 25 3.93±0.11 83.91 
6. 30 3.95±0.22 84.23 
                             
 Immediate Release Layer of Losartan Potassium 
 
S.NO 
 
Time 
(mins) 
Amount of drug release 
               (mg) 
Cumulative Drug release 
                 (%) 
1. 5 29.93±0.29 61.72 
2. 10 34.98±0.12 72.17 
3. 15 37.01±0.45 76.32 
4. 20 39.52±0.26 81.56 
5. 25 40.68±0.47 83.94 
6. 30 41.46±0.19 85.56 
 
 
 
Figure 25:   In vitro Dissolution Profile of Formulation F-5 
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Table 32: In vitro dissolution profile of Bilayer tablet F-6 
                              
Immediate Release Layer of Amlodipine Besylate 
 
S.NO Time 
(mins) 
Amount of drug release 
                (mg) 
 Cumulative Drug release 
                  (%) 
1. 5 3.37±0.08 71.87 
2. 10 3.63±0.12 77.46 
3. 15 3.87±0.10 82.76 
4. 20 3.90±0.18 83.15 
5. 25 3.94±0.19 84.12 
6. 30 3.97±0.17 84.88 
                             
 Immediate Release Layer of Losartan Potassium 
 
S.NO 
 
Time 
(mins) 
Amount of drug release 
               (mg) 
 Cumulative Drug release 
                 (%) 
1. 5 33.53±0.49 69.14 
2. 10 37.27±0.34 76.87 
3. 15 39.52±0.70 81.53 
4. 20 40.82±0.45 84.21 
5. 25 42.13±0.34 86.92 
6. 30 42.23±0.38 87.15 
 
 
     Figure 26:   In vitro Dissolution Profile of Formulation F-6 
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Table 33: In vitro dissolution profile of Bilayer tablet F-7 
                              
Immediate Release Layer of Amlodipine Besylate 
 
S.NO Time 
(mins) 
Amount of drug release 
                (mg) 
Cumulative Drug release 
                (%) 
1. 5 3.31±0.05 70.53 
2. 10 3.67±0.11 78.12 
3. 15 3.81±0.09 81.23 
4. 20 3.87±0.15 82.87 
5. 25 3.93±0.18 84.25 
6. 30 3.95±0.14 84.32 
                             
 Immediate Release Layer of Losartan Potassium 
 
S.NO 
 
Time 
(mins) 
Amount of drug release 
               (mg) 
 Cumulative Drug release  
                (%) 
1. 5 35.94±0.31 74.12 
2. 10 38.14±0.44 78.70 
3. 15 40.82±0.19 84.21 
4. 20 41.98±0.54 86.78 
5. 25 42.95±0.29 88.79 
6. 30 43.17±0.28 89.09 
 
 
 
Figure 27:   In vitro Dissolution Profile of Formulation F- 7 
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Table 34 :In vitro dissolution profile of Bilayer tablet F-8 
                              
Immediate Release Layer of Amlodipine Besylate 
 
S.NO Time 
(Mins) 
Amount of Drug Release  
              (mg) 
Cumulative Drug Release  
                   (%) 
1. 5 3.43±0.06 73.12 
2. 10 3.72±0.08 79.54 
3. 15 3.84±0.14 82.17 
4. 20 3.90±0.12 83.21 
5. 25 3.92±0.11 83.64 
6. 30 3.93±0.15 84.02 
                             
 Immediate Release Layer of Losartan Potassium 
 
S.NO 
 
Time 
(Mins) 
Amount of Drug  Release           
              (mg) 
Cumulative Drug Release 
                    (%) 
1. 5 37.66±0.55 77.67 
2. 10 40.50±0.48 83.82 
3. 15 41.22±0.37 85.05 
4. 20 42.71±0.71 88.12 
5. 25 43.55±0.68 89.85 
6. 30 43.65±0.42 90.08 
 
 
   Figure 28:   In vitro Dissolution Profile of Formulation F-8 
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  Figure 29   In vitro Dissolution Profile of Losartan trials 
 
 
  
Figure 30:  In vitro Dissolution Profile of Amlodipine trials 
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  Table 35: In vitro dissolution profile of Market formulation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 31: Comparison of Dissolution profiles of Optimized Formulation F8  
                    and Marketed formulation 
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F8 Vs Market Product
Amlodipine (F8)
Losartan (F8)
Amlodipine-Market
Product
Losartan-Market
Product
S.No Time 
(mins) 
Cumulative percentage 
drug release for 
Amlodipine 
                (%) 
Cumulative percentage 
drug release for 
Losartan 
              (%) 
1. 5 71.54 76.65 
2. 10 77.36 84.12 
3. 15 78.13 86.41 
4. 20 78.79 89.98 
5. 25 79.12 91.74 
6. 30 79.95 92.56 
Model Chromatograms 
Dissolution 
 
 
  
                            Figure 32:    Dissolution sample 
 
 
                             Figure 33:  Dissolution standard 
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Table 36:Optimized Formulation Parameters- F8 
S.NO Test Optimized Formulation (F8) 
1. Description Yellow 
colour,circular,slightly,biconvex,plain,film 
Coated 
2. Average Weight(Mg) 
 
363±4 
3. Identification Test 
(a) Amlodipine 
Besylate 
(b) Losartan Potassium 
 
(a) Complies 
(b) Complies 
4. Thickness(mm) 4.31±0.014 
5. Assay 
(a) Amlodipine 
Besylate 
(b) Losartan Potassium 
(a)94.70% 
(b)96.87% 
6. Dissolution 
(a) Amlodipine 
Besylate 
(b) Losartan Potassium 
(a)84.02% 
(b)90.08% 
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Table 37:  Stability Studies 
 
S.N
o 
 
Parameters 
                                                                      Conditions 
Initial 
40°C& 
75%RH 
40°C& 
75%RH 
40°C& 
75%RH 
40°C& 
75%RH 
0 Day 1 month 2 month 3 month 6 month 
1 
Average 
weight 
363±5mg 363±5mg 363±5mg 363±5mg 
363±5mg 
2 Thickness(mm) 4.31±0.014 4.31±0.014 4.31±0.014 4.31±0.014 4.31±0.014 
3 
Disintegration 
        time 
  
6min45sec 7min17sec 7min23sec 7min20sec 
 
  7min 55 
sec 
4   Assay(%) 
A-94.70 A-94.66 A-94.49 A-94.45 A-94.21 
L-96.87 L-96.81 L-96.74 L-96.72 L-96.50 
5 
Dissolution 
 (30min) 
A-84.02 A-83.98 A-83.89 A-83.86 A-83.53 
L-90.08 L-89.91 L-89.88 L-89.85 L-89.71 
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                                                                8. Discussion 
 
 
 
8.1. Calibration curves:  
For Amlodipine besylate: 
Calibration curve of Amlodipine besylate was  prepared in 0.1N HCL at determined 
Wavelength 237nm.The calibration curve was linear between 2 to 20 µg/ml concentration 
ranges. The r2 and slope were found to be 0.998 and 0.0323. 
For Losartan Potassium: 
Calibration  curve of Losartan Potassium was  developed in  6.8  pH  buffer  at  above 
determined  wavelength 235nm. The calibration curve was linear between 2 to 20 µg/ml 
concentration ranges. The r2 and slope were found to be 0.9926 and 0.04485. 
8.2. Preformulation studies: 
It is one of the important prerequisite in development of any drug delivery system. 
Preformulation  studies  were  performed  on  the  drug,  which  included  melting  point 
determination, and compatibility studies. 
Physicochemical Interaction of drug and Excipients: 
The FTIR spectra of the drugs and its excipients are depicted in the figure 13-17.The spectra 
of standard Amlodipine Besylate and losartan potassium showed sharp charecteristics peaks at 
3230.19cm-1,1687.41cm-1,2971.75cm-1, 1116.92cm-1 and 3162.79cm-1,1665.69cm-1, 
3163.43cm-1 respectively.These peaks are also prominent in the spectra of the physical 
mixtures containing the drug and excipients in the formula of individual layers. This indicates 
there was no interaction between the drug and excipients. 
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8.3. Precompression studies: 
8.3.1. Angle of repose  
 
The angle of repose for the formulated blend was carried out and the results were shown 
 
in table No.22 and 23. It concludes all the formulations blend for amlodipine besylate   
 
was found to be in the  range 26.30' to 29.40’  and for losartan potassium it was found to be  
 
in the range of 26.20' to 32.50. Hence the entire formulations blend was found to be good,   
 
passable flow property. 
 
 
8.3.2. Compressibility index 
 
Compressibility index was carried out, it was  found between 14.32% to 21.20% for 
Amlodipine besylate blend and 18.19% to 21.89% for losartan potassium blend indicating the 
powder blend has the required flow property for compression. The results were shown in table 
No.22 and 23 
 
8.3.3. Hausner’s ratio: 
 
 
Hausner’s ratio was calculated for the blend, it found between 1.16- 1.27 for  
amlodipine besylate and 1.09-1.26 for losartan potassium indicating Powder blend  
has the required flow property for compression. The results were shown in table No.22 and 23 
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8.5 Evaluation of Bilayer tablets  
The measured hardness of tablets of each batch ranged between 6.4±0.57 to 8.9±0.69 
kg/cm2. This ensures good handling characteristics of all batches. The results were shown in 
Table No.24. The values of friability test were tabulated in Table No.24. The % friability was 
less than 1% in all the formulations ensuring that the tablets were mechanically stable. The 
percentage weight variations for all formulations were tabulated in Table No.26. All the 
formulated (F1 to F8) tablets passed weight variation test as the Percentage  weight variation 
was within the pharmacopoeial limits of 7.5% of the weight. The weights of all the tablets 
were found to be uniform with low standard deviation values. The measured thickness of 
tablets of each batch ranged between 4.09±0.011to4.35±0.010mm for uncoated tablets and 
4.21±0.011 to 4.46±0.012mm for  coated tablets . The results were shown in Table No.24 and 
25. The disintegration time of all the batches were found between 11 minutes to 6 minutes and 
results were shown in Table No 25. The percentage  of  drug  content  for  F1  to  F8  was  
found  to  90.78%  to  94.98%  of  Amlodipine  besylate and 94.79% to 98.15% of Losartan 
Potassium  and it complies with official specifications. The results were shown in table 25. 
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8.5.6. In vitro dissolution study 
 
All the  eight  formulations  of  Amlodipine  besylate  and  losartan potassium  bilayer 
tablets, were  subjected to in vitro release studies. Dissolution  profiles  of  all  
formulations  were  compared  by cumulative  percentage  drug  release  versus  time. 
The percentage release of amlodipine besylate and losartan potassium at the end of  30 
mins for F1 was found to be 73.62% and 68.40% which fails the official limits.The 
percentage release of amlodipine besylate and losartan potassium at the end of  30 mins 
for F2 was found to be 76.15% and 72.2% Respectively. The percentage release of 
amlodipine besylate and losartan potassium at the end of  30 mins for F3 was found to 
be 79.71% and 77.59% respectively.The percentage release of amlodipine besylate and 
losartan potassium at the end of  30 mins for F4 was found to be 79.71% and 77.59% 
respectively. The percentage release of amlodipine besylate and losartan potassium at 
the end of  30 mins for F5 was found to be 84.23% and 85.56% respectively. The 
percentage release of amlodipine besylate and losartan potassium at the end of  30 mins 
for F6 was found to be 84.88% and 87.15% respectively.The percentage release of 
amlodipine besylate and losartan potassium at the end of  30 mins for F7was found to be 
84.32% and 89.09% respectively. The percentage release of amlodipine besylate and 
losartan potassium at the end of  30 mins for F8 was found to be 84.02% and 90.08% 
respectively. From dissolution  results it was confirmed that formulation F8 was 
showing good dissolution profile in comparison to other batches and also according to 
pharmacopoeial  limits. The optimized formulation(F8) was compared with that of 
marketed formulation and the results were found to be satisfactory. 
                 The optimized formulation F8 containing  5 % w/w crospovidone  for Losartan    
       Potassium layer and 4% Sodium Starch Glycolate for Amlodipine layer shows least  
       disintegration time and better dissolution properties compared to the other trail batches 
       (F1- F7). The reason might be at the optimum concentration crospovidone rapidly      
       exhibits high capillary action and pronounced hydration capacity and at optimum      \           
       concentration of sodium starch glycolate disintegration occurs by rapid uptake of water    
        followed by rapid  and enormous swelling and hence F8 was choosen as the  optimized  
       formulation for the further stability studies. 
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   8.6. Stability study 
 
According to ICH guidelines, 6 months accelerated stability study at 40±2°c and 75±5%                                         
RH optimized formulation (F8) showed negligible change over time for parameters       
 like appearance, drug content, dissolution, etc. No significant difference in the drug      
content between initial and formulations stored at 40±2°& 75±5% RH for 6 months. 
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                                                               SUMMARY  
 
 
 
Amlodipine is a long-acting dihydropyridine calcium channel blocker. It is effective 
in the treatment of angina pectoris and hypertension, which has a biological half life of 
30- 
50 hours. Its dose is 2.5 to 10mg daily in divided doses. Losartan is a selective 
angiotensin II  receptor blocking agent.  It is useful mainly treatment of  
hypertension. It has a short biological half life of 2  hours and its dose is 40-80mg 
daily in divided doses.  
 
In the present study an attempt was made to prepare Bilayer tablets of Amlodipine 
besylate  (IR) and  Losartan Potassium(IR) with excipients like MCC pH 102,  SSG, 
aerosil & magnesium stearate for Amlodipine release layer and starch 1500, 
Crospovidone XL 10, aerosil & magnesium stearate for Losartan release layer. 
 
Prepared bilayered tablets were evaluated for hardness, friability, weight variation, 
drug content  uniformity, Drug-excipient  interaction,  in  vitro  drug  release  and  
stability studies. Among  the various formulations prepared, Formulation F8 with 
SSG (4%) for amlodipine release and, (5 %)   o f  crospovidone XL 10 for losartan release 
 Showed comparatively good release which complies with the dissolution requirements. 
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                                       CONCLUSION 
 
The present research was carried out to develop a Immediate Release Bilayer tablet of 
Amlodipine Besylate and Losartan Potassium. Combination of Amlodipine Besylate and 
Losartan Potassium are indicated for the successful treatment and relief of hypertension. 
Prepared bilayer tablets were film coated in a conventional coating pan. Formulation 
characteristics such as content uniformity, hardness, friability were found to be satisfactory 
In vitro dissolution studies of bilayer tablets were conducted for 30 minutes. Samples 
were analyzed by HPLC. The formulation (F-8) showed acceptable pharmacotechnical 
properties and complied with the internal specification for weight variation, thickness, 
hardness, friability, drug content and in vitro drug release. Reproducibility was checked by 
intra batch variability study and found no pronounced variation was observed. 
Accelerated stability profile of bilayer tablets were found to be satisfactory. No sign of 
degradation was observed in HPLC analysis. Hence, it is finally concluded that, the Bilayer 
tablet technology can be successfully applied for Immediate-release of Amlodipine Besylate 
and Losartan Potassium. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                             
114 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                             12. BIBLIOGRAPHY 
1. Chien YW. Fundamentals of controlled-release of drug administration. In: Swarbrick 
J. ed. Novel Drug Delivery System, Marcel Dekker, Inc., New York, 1982; 465–574. 
2. Buri P, Puisicux F, Doelker E, Benoit JP. Formes Pharma centiques Nouvelles, ed. 
Technique et Documentation, Lavoisier, Paris, 1985. 
3. Jayanthi B, Manna PK, Madhusudhan S, Mohanta GP, Manavalam R. Per oral 
extended releases products-an overview. Journal of Applied Pharmaceutical Science. 
2011; 1(2): 50-5. 
4. Lee L. Diffusion-controlled matrix systems. In: Kydonieus A. ed. Treatise on 
Controlled Drug Delivery, Marcel Dekker, Inc., New York, 1992, 155– 98. 
5. Peppas NA. Hydrogels in Medicine and Pharmacy, vols. I, II and III, CRC Press,   
Boca Raton FL, 1988. 
6. Jha AK, Bhattacharya A, Verma P. Formulation and in vitro evaluation of sustained 
release matrix tablets of metoprolol succinate using hydrophilic polymers. 
International Journal of PharmTech Research. 2009; 1(4): 972-77. 
7. Prajapati SK, Richhaiya R, Singh VK, Singh AK, Kumar S, Chaudhary RK. 
Formulation and evaluation of once daily sustained release matrix tablet of 
aceclofenac using natural gums. Journal of Drug Delivery and Therapeutics. 2012; 
2(1): 16-24. 
8. Ganesh S, Radhakrishnan M, Ravi M, Prasannakumar B, Kalayani J. In vitro 
evaluation of the effect of combination of hydrophilic and hydrophobic polymers on 
controlled release zidovudine matrix tablets. Indian J Pharm Sci. 2008; 70(4): 461-5. 
9. Enayatifard R, Saeedi M, Akbari J, Tabatabaee YH. Effect of hydroxypropyl 
methylcellulose and ethyl cellulose on release profile and kinetics of diltiazem HCl 
from matrices. Tropical Journal of Pharmaceutical Research. 2009; 8(5): 425-32. 
10. Derakhshandeh K, Soleymani M. Formulation and in vitro evaluation of nifedipine-
controlled release tablet: Influence of combination of hydrophilic and hydrophobic 
matrix forms. Asian Journal of Pharmaceutics. 2010; 4(4): 185-93.  
11. Wadher KJ, Kakde RB, Umekar M. Formulation of sustained release metformin 
hydrochloride matrix tablets: Influence of hydrophilic polymers on the release rate and 
in vitro evaluation. International Journal of Research in Controlled Release.2011                                                                                                                     
115 
12. Narasimaharao R, Anusha RM, Swetha RN, Divyasagar P, Keerthama K. Design and 
evaluation of metformin hydrochloride extended release tablets by direct compression. 
International Journal of Research in Pharmaceutical and Biomedical Sciences. 2011; 
2(3): 1118-33. 
13. Bhardwaj L, Sharma PK, Malviya R. A short review on gastro-retentive formulation 
for stomach specific drug delivery: Special emphasis on floating in situ gel systems. 
African Journal of Basic and Applied Sciences. 2011; 3(6): 300-12. 
14. Shaikh RP, Pillay V, Choonara YE, Toit LC, Ndeseudo VMK, Bawa P, Cooppan S. A 
review on multi-responsive membranous systems for rate-modulated drug delivery. 
AAPS PharSciTech. 2010; 11(1): 441-59. 
15. Bansal V, Sharma PK, Sharma N, Pal OP, Malviya R. Applications of chitosan and 
chitosan derivatives in drug delivery. Advances in Biological Research. 2011; 5(1): 
28-37. 
16. Iqbal Z, Khan R, Nasir F, Khan JA, Rashid A, Khan A, Khan A. Preparation and in 
vitro in vivo evaluation of sustained release matrix diclofenac sodium tablets using 
PVP-K90 and natural gums. Pak. J. Pharm. Sci. 2011; 24(4): 435-43. 
17. Goyel M, Prajapati R, Purohit KK, Mehta SC. Floating drug delivery system. Journal 
of Current Pharmaceutical Research. 2011; 5(1): 7-18. 
18. Alderman D. A review of cellulose ethers in hydrophilic matrices for oral              
controlled-release dosage forms, Int. J. Pharm. Prod. Manuf. 1984; 5: 1– 9. 
19. Salomon JL, Vaugnat P, Doelker E, Buri P. Importance de la technologie et de la 
formulation pour le mechanisme de liberation du chlorure de potassium contenu dans 
des matrices hydrophiles. Pharm Acta. Helv. 1979; 3: 86–9. 
20. Kim C. Controlled release from triple layer, donut-shaped tablets with enteric 
polymers. AAPS PharmSciTech. 2005; 6(3): 429-36. 
21. Alagusundaram M, Chetty CM, Dhachinamoorthi D. Development and evaluation of 
novel trans-mucoadhesive bilayer tablets of famotidine. Asian Journal of 
Pharmaceutics. 2011; 5(3): 150-6. 
22. Patel D, Patel A, Solanki T. Formulation and evaluation of bilayer tablet by using melt 
granulation technique for treatment of diabetes mellitus. Journal of Pharmacy and 
BioAllied Sciences. 2012; 4(5): 37-9. 
                                                                                                                            116 
23. Shrikant M, Shah S, Upadhyay P. Floating bilayer drug delivery systems-an 
unconventional approach in conventional form. American Journal of PharmTech 
Research. 2012; 2(2): 609-28. 
24. Naeem MA, Mahmood A, Khan SA, Shahiq Z. Development and evaluation of 
controlled-release bilayer tablet containing microencapsulated tramadol and 
acetoaminophen. Tropical Journal of Pharmaceutical Research. 2010; 9(4): 347-54.  
25. Silva JPS, Lobo JS, Bonifàcio MJ, Machado R, Falcão A, Soares-da-Silva P. In vitro 
evaluation of prolonged release bilayer tablets of anti-parkinson drugs in Göttingen 
minipigs. Journal of Pharmacy and Pharmacology 2011; 63(6): 780-5. 
26. Negi JS, Khanduri P, Trivedi A, Negi V, Singh V. Effects of psylium husk on floating 
behavior of atenolol bilayer tablets. International Journal of Comprehensive 
Pharmacy. 2011; 4(6): 1-4. 
27. Mehrgan H, Mortazavi SA. The release behavior and kinetic evaluation of diltiazem 
HCl from various hydrophilic and plastic based matrices. Iranian Journal of 
Pharmaceutical Research. 2005; 4(3): 137-46. 
28. Engineer C, Parikh J, Raval A. Review on hydrolytic degradation behavior of 
biodegradable polymers from controlled drug delivery system. Trends Biomater. Artif. 
Organs. 2011; 25(2): 79-85. 
29. Fu Y, Kao WJ. Drug release kinetics and transport mechanism of non-degradable and 
degradable polymeric drug delivery systems. Expert Opin Drug Deliv. 2010; 7(4): 
429-44. 
30. Moodley K, Pillay V, Choonara YE, duToit LC, Ndesendo VMK, Kumar P, Cooppan 
S, Bawa P. Oral drug delivery systems comprising altered geometric configuration for 
controlled drug delivery. Int. J. Mol. Sci .2012; 13(1): 18-43. 
31. Mughal MA, Iqbal Z, Neau SH. Guar gum, xanthan gum, and HPMC can define 
release mechanisms and sustain release of propanolol hydrochloride. AAPS 
PharmSciTech. 2011; 12: 77-87. 
32. Rao NGR, Yadav A, Kulkarni U. Formulation and evaluation of zero-order release 
glipizide bilayer matrix tablets using natural and synthetic polymers. International 
Journal of Current Pharmaceutical Research. 2010; 2(1): 34-42. 
 
 
                                                                                                                                        117 
33. Sibambo SR, Pillay V. Kinetic and structural modeling mechanisms of melatonin 
transport from an electrolytically regulated salted out PLGA scaffold. Journal of 
Bioactive and Compatible Polymers. 2009; 24: 266-96. 
34. Streubel A, Siepmann J, Peppas NA, Bodmeier R. Bimodal drug release achieved with 
multi-layer matrix tablet: transport mechanisms and device design. J. Control Release. 
2000; 69(3): 455-68. 
35. Ahmed SI, Mangamoori LN, Rao YM. Formulation and characterization of matrix and 
triple-layer matrix tablets for oral controlled drug delivery. International Journal of 
Pharmacy and Pharmaceutical Sciences. 2010; 2(3): 137-43. 
36. Baloğlu E, Şenyiğit T. A design and evaluation of layered matrix tablet formulations 
of metoprolol tartarate. AAPS PharSciTech. 2010; 11(2): 563-73. 
37. Aminabhavi TM, Patil GV, Balundgi RH, Harlapur SF, Manvi FV, Bhaskar C. A 
review on the sustained release of cardiovascular drugs through hydroxypropyl 
methycellulose and sodium carboxymethycellulose polymers. Designed Monomers 
and Polymers. 1998; 1(4): 347-72.  
38. Phaechamud T, Yodkhum K, Ritthidej G. Drug release, water sorption, and erosion 
behavior of three-layered matrix tablets consisting of chitosan and xanthan gum. Asian 
Journal of Pharmaceutical Sciences. 2008; 3(6): 260-8. 
39. Rao KS, Jadhav S, Patil P, Dattataya BU. Development and evaluation of sustained 
release formulations of venlafaxine hydrochloride. International Journal of Research in 
Ayurveda and Pharmacy. 2011; 2(3): 948-60. 
40. Krishnaiah YSR, Karthikeyan RS, Bhaskar P, Satyanarayana V. Bioavailability 
studies on guar gum-based three-layer matrix tablets of trimetazidine dihydrochloride 
in human volunteer. J. Control Release. 2002; 83: 231– 9. 
41. Maggi L, Morgenthaler S, Zimmer R, Shepard T, Conte U. Human evaluation of 
Quick/Slow drug delivery technology: a new therapeutic approach, Proceedings of the 
22nd International Symposium on Controlled Release of Bioactive Materails, Seattle, 
USA, July 31 –August 2, 1992, 208– 9. 
42. Maggi L, Shepard T, Rochdi M, Grenier P, Halbeisen S, Zimmer R, Conte U. A 
simulation approach for efficient development of a naproxen Geomatrix Quick/Slow 
formulation, Proceedings of the 24th International Symposium on Controlled Release 
of Bioactive Materials, Stockholm, Sweden, June 15– 19, 1997,  327– 8. 
                                                                                                                                     118 
43. Conte U, La Manna A, Maggi L. Pharmaceutical tablet capable of liberating one or 
more drugs at different release rates, PCT Int. Appl. WO 94/06416, 31 March 1994. 
44. Maroni A, Zema L, Carea M, Sangalli ME. Oral pulsatile drug delivery systems. 
Expert Opin Drug Deliv. 2005; 2(5): 855-71. 
45. Dusane AR, Gaikwad PD, Bankar VH, Pawar SP. A review on: Sustained released 
technology. International Journal of Research in Ayurveda and Pharmacy. 2011; 2(6): 
1701-8. 
46. Dalvadi H, Patel JK. Chrnopharmaceutics, pulsatile drug delivery system as current 
trend. Asian Journal of Pharmaceutical Sciences. 2010; 5(5): 207-30. 
47. Bauskar MD, Nandedkar SY, Wagh RD. Formulation design and optimization of 
pulsatile release tablet of acebrophylline with swelling and erodiable layers for 
treatment of nocturnal bronchial asthma. International Journal of Pharmaceutical 
Sciences and Research. 2011; 2(12): 3100-8. 
48. Jagdale SC, Sali MS, Barhate AL, Loharkar JN, Chabuskar AR. Design and evaluation 
of enteric press-coated tablet for pulsatile delivery of atenolol. International Journal of 
Pharma World Research. 2010; 1(2): 1-15. 
49. Abdul S, Poddar SS.  A flexible technology for modified release of drugs: Multi-
layered tablets. Journal of Control Release. 2004; 97(3): 393-405.  
50. Fukui E, Uemura K, Kobayashi M. Studies on applicability of press-coated tablets 
using hydroxypropylcellulose (HPC) in the outer shell for timed release preparations. 
J. Control. Release. 2000; 68(2): 215-23. 
51. Jain D, Raturi R, Jain V, Bansal P, Singh R. Recent technologies in pulsatile drug 
delivery systems. Biomatter. 2011; 1(1): 57-65. 
52. Zou H, Jiang X, Kong L, Gao S. Design and evaluation of a dry coated drug delivery 
system with floating-pulsatile release. Journal of Pharmaceutical Sciences. 2008; 
97(1): 263-73. 
53. Conte U, La Manna A, Maggi L. Pharmaceutical tablets releasing the active 
substances after a definite period of time, U.S. patent 5,464,633, November 7, 1995. 
54. Waterman KC, Ferqione MB. Press-coating of immediate release powders onto coated 
controlled release tablets with adhesives. J. Control. Release. 2003; 89(3): 387-95. 
 
 
                                                                                                                                     119 
55. Rane AB, Gattani SG, Kadam VD, Tekade AR. Formulation and evaluation of press 
coated tablets for pulsatile drug delivery using hydrophilic and hydrophobic polymers. 
Chem Pharm Bull. 2009; 57(11): 1213-7. 
56. Gohel MC, Soni CD, Nagori SA, Sarvaiya KG. Modulation of venlafexine 
hydrochloride release form press coated matrix tablet. Indian J. Pharm Sci. 2008; 
70(3): 292-7.  
57. Fukui E, Uemura K, Kobayashi M. Studies on applicability of press-coated tablets 
using hydroxypropylcelluose in the outer shell for timed-release preparation. J. 
Control. Release. 2000; 68: 215– 23. 
58. Fukui E, Miyamura N, Kobayashi M. An in vitro investigation of the suitability of 
press-coated tablets with hydroxypropylmethylcellulose acetate succinate (HPMCAS) 
and hydrophobic additives in the outer shell for colon targeting. J. Control Release. 
2001; 70: 97– 107. 
59. Latha K, Sunil MUSA, Srikanth MV, Murthy KVR. Development of an optimized 
losartan potassium press coated tablets for chronotherapeutics drug delivery. Tropical 
Journal of Pharmaceutical Research. 2011; 10(5): 551-8. 
60. Junginger HL. Oral applications of pulsatile drug delvery. In: Gurny R, Junginger HL, 
Peppas NA. ed. Pulsative Drug Delivery-Current Application and Future Trends, 
Wissenschaftliche Verlagsagesellschaft, Stuttgart, 1993, 113–4. 
61. Vinayagamkannan, Ragupathikandarapu, Garg S. Optimization techniquies for the 
design and development of novel drug delivery systems- part I. Pharm Technol. 2003; 
27(2): 74–90. 
62. Vinayagamkannan, Ragupathikandarapu, Garg S. Optimization techniquies for the 
design and development of novel drug delivery systems- part II. Pharm. Technol. 
2003; 27(3): 102–18. 
63. Davis SS, Hardy JG, Fara JW. Transit of pharmaceutical dosage forms through the 
small intestine. Gut 1986; 27: 886– 92. 
64. Fell JT, Newton JM. Determination of tablets strength by the diametral-compression 
test. J. Pharm Sci. 1970; 59: 688– 91. 
65. Cremer K, Asmussen B. Novel Controlled-release tablet with erodible layers. Proc. 
Int. Control. Release Bioact. Mater. 1995; 22: 732–3. 
 
                                                                                                                                        120 
66. Pattanayak DP, Dinda SC. Bilayer tablet formulation of metformin HCl and 
glimepiride: A novel approach to improve therapeutic efficacy. Int J Drug Discovery 
Herb Res. 2011; 1(1): 1-4. 
67. Ramesh DS, Guruvaiah, Harani A. Formulation and evaluation of bilayer sustained 
release matrix tablets of metformin Hcl and pioglitazone. Amer-Euras J Sci Res. 2010; 
5(3): 176-82. 
68. Gohel MC, Parikh RK, Nagori SA, Jethwa BA. Fabrication and evaluation of bilayer 
tablet containing conventional paracetamol and modified release diclofenac sodium. 
Ind J Pharm Sci. 2010; 72(2): 191-6. 
69. Naeem MA, Mahmood A, Khan SA, Shahiq Z. Development and evaluation of 
controlled release bilayer tablets containing microencapsulated tramadol and 
acetaminophen. Trop J Pharm Res. 2010; 9(4): 347-54. 
70. Nagaraju R, Kaza R. Formulation and evaluation of bilayer sustained release tablet of 
salbutamol and theophylline. Int J Pharm Sci Nanotechno. 2009; 2(3): 638-46. 
71. Atram SC, Udavant YK, Salunke RJ, Neb GB, Shahi SR, Gulecha BS, Padalkar AN. 
Formulation and evaluation of bilayer tablet containing metoprolol succinate and 
amlodipine besylate as a model drug for anti hypertensive therapy. J Pharm Res. 2009; 
2(8): 1335-47. 
72. Kulkarni AS, Manish S. Design and floating bilayer tablets of diltiazen HCl and 
lovastatin. PDA J Pharm Sci Technol. 2008; 62(5): 344-52. 
73. Nirmal J, Sasivam S, Peddanna C, Muralidharan S, Kumar SG, Nagarajan M. 
Formulation and evaluation of bilayer tablets of atorvastatin calcium and nicotinic 
acid. Chem Pharm Bull (Tokyo). 2008; 56(10): 1455-58. 
74. Shiyani B, Gattani S, Surana S. Formulation and evaluation of bi-layer tablet of 
metoclopramide hydrochloride and ibuprofen. AAPS Pharm Sci Tech. 2008; 9(3): 
818-27. 
75. Jain J, Marya BH, Patavi MR, Patel M. Formulation and evaluation of indomethacin 
bilayer sustained release tablets. International Journal of PharmTech Research. 2011; 
3(2): 1132-8.                     
76. Derle D, Joshi O, Pawar A, Patel J, Jagadale A. Formulation and evaluation of 
bucoadhesive bi-layer tablet of propanolol hydrochloride. International Journal of 
Pharmacy and Pharmaceutical Sciences. 2009; 1(1): 206-12. 
                                                                                                                                         121 
77. Kumar BV, Prasad G, Ganesh B, Swathi C, Rashmi A, Reddy A. Development and 
evaluation of guaif nsin bilayer tablet. International Journal of Pharmaceutical 
Sciences and Nanotechnology. 2010; 3(3): 1122-8. 
78. John AS, Sathesh BPR, Divakar G, Jangid MK, Purohit KK. Development and    
evaluation of bucoadhesive drug delivery system of atorvastatin calcium. Journal of 
Current Pharmaceutical Research. 2010; 1: 31-8. 
79. Patra CN, Kumar AB, Pandit H, Singh SP, Devi MV. Design and evaluation of    
sustained release bilayer tablets of propanolol hydrochloride. Acta Pharm. 2007; 57: 
479- 
80. Karwa P, Kasture PV. Formulation and in vitro evaluation of bilayer tablets of     
zolpidem tartarate for biphasic drug release. International Journal of PharmTech     
Research. 2011; 3(4): 1919-29. 
81. Bandari S, Eaga CM, Thadishetty A, Yamsani MR. Formulation and evaluation of 
multiple tablet as a biphasic gastro retentive floating drug delivery system for           
fenoverine. Acta Pharm. 2010; 60: 89-97. 
82. Londhe S, Gattani S, Suresh S. Development of floating drug delivery system with 
biphasic release for verapamil hydrochloride: In vitro and in vivo evaluation. Journal 
of Pharmaceutical Sciences and Technology. 2010; 2(11): 361-7.  
83. Bhavesh S, Surendra G, Sanjay S. Formulation and evaluation of bilayer tablet of 
metoclopramide hydrochloride and ibuprofen. AAPS Pharm Sci Tech. 2008 
sep;9(3):818-27. 
84. Nagaraju R, Rajesh K. Formulation and evaluation of bilayer sustained release tablets 
of salbutamol and theophylline. Int J Pharm. 2009 Oct-Dec;2(3):638-45. 
85. Saleh M, Al-Saidan, Yellela SRK, Srinivas SP, Vemulapalli S. In vitro and in vivo 
evaluation  
of guar gum matrix tablets for oral controlled release of water-soluble diltiazem 
hydrochloride. AAPS Pharm Sci Tech .2005;6(1):E14-21. 
86. Chinam NP, Arethi BK, Hemanth KP, Satya PS, Meduri VD. Design and evaluation 
            of  sustained  release bilayer tablets of propranolol hydrochloride. Acta Pharm.  
            2007;57:479-89. 
122 
87. Faith AC, Sandile MMK, Roderick B, Walker. Swelling, erosion and drug release      
            characteristics of salbutamol sulfate from hydroxypropyl methylcellulose based matrix      
             tablets. Drug Dev Ind Pharm. 2010;36(12):1497–510.                                                                                                      
88. Uttam M, Tapan KP. Formulation and in vitro studies of a fixed-dose combination of a 
bilayer matrix tablet containing metformin HCl as sustained release and glipizide as 
immediate release. Drug Dev Ind Pharm. 2008;34:305–13. 
89. Raghuram RK, Srinivas M, Srinivas R. Once-daily sustained-release matrix tablets of 
nicorandil formulation and in vitro evaluation. AAPS Pharm Sci. Tech 2003;4(4):1-9. 
90. Anna K, Lennart P, Frida I, Bengt W, Anette L. Influence of different polymer types 
on the overall release mechanism in hydrophilic matrix tablets. molecules 
2009;(14):2699-716. 
91. Jose MCB, Yareli PS, Aracely SM, Karla ED, Marco A, et al. Hydrophobic weak acid 
polymers as controlled release carriers. Pharm Dev Tech. 2010;1–7. 
92. Vanna S, Elisabetta G, Paolo G. Bilayer tablets based on poly (e-caprolactone) and       
polymethylmethacrylates as controlled-release systems for ruminants. Pharm Dev Tech. 
2004;9(3):321–8. 
93. Mukesh G, Shital H, Bariya. Advanced formulation design of venlafaxine 
hydrochloride coated and triple-layer tablets containing hypromellose. Pharm Dev 
Tech. 2009;14(6):650-58. 
94. Yassin ESH, Mona HA. Design and in vitro evaluation of novel sustained-release 
matrix tablets for lornoxicam based on the combination of hydrophilic matrix formers 
and basic ph modifiers. Pharm Dev Tech. 2010;15(2):139–53. 
95. Chuan YW, Jonathan PK, Seville. A comparative study of compaction properties  
            of binary and bilayer tablets. Powder Technol. 2009;189:285–94. 
96. Harikrishna B, Ravi KN, Dionysios D. Development and release mechanism of 
diltiazem hcl prolonged release matrix tablets. Drug Del. 2009;16(2):67–74. 
97. S.Jayaprakash, S. Mohamed Halith, K.Kulathuran Pillai, Priya Balasubramaniyam, 
P.U.   
Mohamed Firthouse, M .Boopathi, Formulation and evaluation of bilayer tablets of 
amlodipine besilate and metprolol succinate, Scholars Research Library Der 
Pharmacia Lettre, 2011,  3 (4), 143-154. 
123 
98. Vaijanath G. Dongre, Sweta B. Shah, pravin P. Karmuse,Manisha Phadke, Vivek K.   
Jadhav Simultaneous determination of metoprolol succinate and amlodipine besylate 
in pharmaceutical dosage form by HPLC, Journal of pharmaceutical and Biomedical 
Analysis.  2008, 46, 583-586. 
                                                                                                                                             
99. CH.M.M. Prasada Rao , S.A.Rahaman ,Y.Rajendra Prasad , P. Gangi Reddy, RP-
HPLC    
method of simultaneous estimation of Amlodipine Besylate and Metoprolol in 
combined dosage form, International journal of pharma.Research and Development. 
2010,2(9) 69-76 
    100.V.Rajamanickam, B.Stephen Rathinaraj, N.Thangavelpandian1, Ananda Rajagopal  
Pandian,   A validated RP-HPLC method of Metoprolol Succinate and Amlodipine 
Succinate from   bulk drugs, Amlodipine Succinate from bulk drugs. Scholars 
Research Library Der  Pharmacia Lettre. 2010, 2(4), 40-46 
    101.M .Paneerselvam, R.Natarajan, S.Selvarajan and N.N.Rajendran. A Novel drug-drug     
            solid   dispersion of Hydrochlorothiazide Losartan Potassium, International Journal of            
             Pharma and  Bio Sciences. 2010, 1(4), 68-80 
    102. Chuan-Yu Wu, Jonathan, P.K. Seville P.K, A comparative study of compaction         
            properties   of binary and bilayer tablets. Powder Technology.2009, 189, 285–294. 
    103. Jakkie, Van der Watt G, Melgardt, De Villier M, The effect of V-mixer scale-up on          
            the   mixing of magnesium stearate with direct compression microcrystalline cellulose.       
    European Journal of Pharmaceutics and Biopharmaceutics.1997, 43, 91-94. 
    104. Calum R. Park, Dale Munday L, Development and evaluation of a biphasic buccal   
           adhesive  tablet for nicotine replacement therapy. International Journal of        
          Pharmaceutics, 2002, 237,215–226. 
   105. Miyazaki S, Kawasaki N, Nakamura T, Iwatsu M, Hayashi T,  Hou W M, Attwood D,     
         Oral mucosal bioadhesive tablets of pectin and HPMC: invitro and in vivo evaluation.    
         International Journal of Pharmaceutics.2000, 204, 127–132. 
  106. Anil Chaudhary, Neha Tiwari, Vikas Jain, Ranjit Singh. Microporous bilayer osmotic  
         tablet  for colon-specific delivery, Eur. J. Pharm. Biopharm. 2011, 78, 134-140. 
  107. Carmen Remun Lopez, Ana Portero, Jose Luis Vila-Jato, Marıa Jose, Alonso Design     
         and   evaluation of chitosan ethylcellulose mucoadhesive bilayered devices for buccal  
 124 
           drug   delivery. Journal of Controlled Release.1998, 55, 143–152. 
  108. Yong Shao, Yongdong Jin, Jianlong Wang, Li Wang, Feng Zhao, Shaojun Conducting   
         polymer polypyrrole supported bilayer lipid membranes Dong. Biosensors and    
         Bioelectronics, 2005, 20, 1373–1379. 
                                                                                  
 109. Fridrun Podczecka, Emad Al-Mutib the tensile strength of bilayered tablets made from     
       different grades of microcrystalline cellulose. European Journal of Pharmaceutical     
       Sciences. 2010, 41, 483–488. 
110. Ajit Kulkarni and Manish Bhatia Development and evaluation of regioselective bilayer   
       floating tablets of Atenolol and Lovastatin for biphasic release profile Iranian Journal of   
      Pharmaceutical Research.2009, 8 (1), 15-25. 
111. A. Streubel J. Siepmann,, N.A. Peppas, R. Bodmeier, Bimodal drug release achieved  
       with multi-layer matrix tablets:  transport mechanisms and device design, Journal of  
        Controlled   Release.2000,69,455–468. 
112. Rashmi Dahima, Ashish Pachori, Sanjay Netam, formulation and evaluation of mouth 
        dissolving tablet containing amlodipine besylate solid dispersion, International Journal   
       of  Chem Tech Research.2010, 2(1), 706-715. 
113. MA Naeem, A Mahmood, SA Khan and Z Shahiq, Development and Evaluation of      
       Controlled-Release Bilayer Tablets Containing Microencapsulated Tramadol and    
       Acetaminophen, Tropical Journal of Pharmaceutical Research. August,2010, 
       9 (4), 347-354. 
 114.  Libo Yang , Gopi Venkatesh , Reza Fassihi, Compaction simulator study of a novel                    
         triple layer tablet matrix for industrial tableting, International Journal of Pharmaceutics.       
         1997,152,  45-52. http://www.drugbank.com. 
 115. http://www.drugbank.com. 
 116. http://www.wikipedia.com. 
 117. Handbook of Pharmaceutical excipients 5th edn; 2006, 346-349 
 118. Handbook of Pharmaceutical excipients 5th edn; 2006, 701-704 
 119. Handbook of Pharmaceutical excipients 5th edn; 2006, 188-191 
 120. Handbook of Pharmaceutical excipients 5th edn; 2006, 214-216 
 121. Handbook of Pharmaceutical excipients 5th edn; 2006, 132-135 
                                                                                                                                         125 
  122. Handbook of Pharmaceutical excipients 5th edn; 2006, 725-730 
 123. Handbook of Pharmaceutical excipients 5th edn; 2006, 371-373 
 124. Handbook of Pharmaceutical excipients 5th edn; 2006, 430-433 
 125. Handbook of Pharmaceutical excipients 5th edn; 20096, 96-99 
 126. Handbook of Pharmaceutical excipients 5th edn; 2006, 731-733 
127. Lachman L., Lieberman HA., Kanig JL., The theory and practice of industrial        
        pharmacy; Varghese Publishing House Bombay; 1987; 293-345, 430. 
 128. Indian Pharmacopoeia. Government of India, Ministry of health and family welfare,  
         Published by the controller of publications, Delhi, 2007; Volume I &II. 
129. VineetBhardwaj, MayankBansal, Sharma PK. Formulation and Evaluation of Fast      
       Dissolving Tablets of Amlodipine Besylate Using Different Super Disintegrants and    
        Camphor as Sublimating Agent. American-Eurasian Journal of Scientific Research 2010;   
       5 (4): 264-269 
 
 
 
 
  
 
 
 
 
 
 
 
                                                                                                                                126 
 
 
 
 
 
 
